DRUG NAME: Finerenone

ℹ️ INN (International Nonproprietary Name): Finerenone. USAN: Finerenone (same as INN). No alternate naming conventions apply in Indian practice.

Therapeutic Class: Mineralocorticoid Receptor Antagonist

New class — Justification required per formulary rules:

Finerenone does not fit any existing standardised therapeutic class on the approved list:

Not “Diuretic” — finerenone has no natriuretic or diuretic action whatsoever (unlike the steroidal MRA spironolactone, which retains potassium-sparing diuretic properties).
Not “Antihypertensive” — its blood-pressure-lowering effect is modest (~2–3 mmHg systolic) and incidental; it is not CDSCO-approved for hypertension.
Not “Antidiabetic” — it does not lower blood glucose or HbA1c.
Not “Immunosuppressant” — although its mechanism is anti-inflammatory and anti-fibrotic, it does not suppress adaptive immunity.

The proposed class “Mineralocorticoid Receptor Antagonist” reflects the pharmacological action at the receptor level and can accommodate both steroidal (spironolactone, eplerenone) and non-steroidal (finerenone) agents, which are increasingly recognised as a distinct pharmacological class with divergent clinical applications (haemodynamic/volume management vs organ-protective/anti-fibrotic roles).

Subclass: Non-steroidal mineralocorticoid receptor antagonist (ns-MRA)

Finerenone is the first approved non-steroidal MRA. It lacks the steroidal scaffold of spironolactone and eplerenone, conferring higher MR selectivity, absence of anti-androgenic effects, and no natriuretic action. (Detailed mechanistic discussion: see Unique Pharmacological Properties Note in Pharmacokinetics section below.)

Schedule (India): Schedule H

Prescription-only medicine. Standard pharmacist dispensing requirements apply. Not a Schedule H1 or Schedule X drug. No NDPS Act compliance requirements.

Route(s)

Oral

Film-coated tablets for oral administration only.

Route exclusion rationale: No parenteral (IV, IM, SC), inhaled, topical, or any other non-oral formulation of finerenone exists globally or in India. Finerenone is designed exclusively for chronic oral administration in ambulatory patients. There is no clinical need for a parenteral formulation — the drug is not used in acute/emergency settings. In hospitalised patients temporarily unable to take oral medications, finerenone should be held and resumed when oral intake is possible. There is no parenteral MRA substitute with equivalent cardiorenal evidence; holding finerenone for a few days during acute illness is acceptable.

Biosimilar Status:

Not a biologic — biosimilar classification not applicable. Finerenone is a small-molecule chemical drug (molecular weight: 422.5 Da). Standard generic pharmaceutical regulatory pathway applies under CDSCO rules for new chemical entities and subsequent generic approvals.

Formulations Available in India

Single-ingredient formulations:

Dosage Form	Strengths Available	Notes
Film-coated tablet (oral)	10 mg	Lower starting dose; used when baseline eGFR 25 to <60 mL/min/1.73 m²
Film-coated tablet (oral)	20 mg	Higher dose; used when baseline eGFR ≥60 mL/min/1.73 m² or after titration from 10 mg

ℹ️ Only two strengths are available. Dose selection depends on baseline eGFR and serum potassium — see Indications + Dosing.

Formulation verification: Strengths verified against Kerendia (Bayer Zydus Pharma) product information for the Indian market. 10 mg and 20 mg film-coated tablets confirmed as the only marketed strengths in India.

Administration considerations:

Tablets should be swallowed whole with water.
⚠️ The manufacturer does not recommend crushing, splitting, or chewing the film-coated tablets. Data on administration via nasogastric tube, crushed in food, or dispersed in water is not available in the approved product information. If a patient cannot swallow whole tablets, consult clinical pharmacy for alternatives or consider holding the drug if clinically appropriate.

Injectable formulations: Not applicable — no injectable formulation of finerenone exists.

Device-delivered formulations: Not applicable.

Fixed-Dose Combinations (FDCs): No CDSCO-approved FDCs containing finerenone are currently available in India. No irrational or banned FDCs containing finerenone have been identified.

Banned/withdrawn formulations: No formulations or FDCs containing finerenone have been banned or withdrawn by CDSCO as of the date of this monograph.

PHARMACOKINETICS

Main Pharmacokinetic Parameters

Parameter	Value	Clinical Relevance
Bioavailability (oral)	~44% (fasted state); increases to ~53% with food (high-fat, high-calorie meal: AUC ↑~21%, Cmax ↑~19%)	Recommend taking with food for more consistent drug exposure
Tmax	0.5–1.25 hours (median ~1 hour)	Rapid oral absorption
Protein binding	~92% (primarily to serum albumin)	Clinically significant increase in free fraction expected in hypoalbuminaemia (see Population PK)
Volume of distribution (Vd)	~52.6 L (apparent Vss/F)	Moderate tissue distribution; balanced cardiac and renal penetration (see Unique Pharmacological Properties Note)
Metabolism	Hepatic: CYP3A4 (~90% contribution), CYP2C8 (~10% contribution). Four identified metabolites (M1, M2, M3, M4) — all pharmacologically inactive at the MR at clinically relevant concentrations	⛔ Strong CYP3A4 inhibitors and inducers: CONTRAINDICATED. Moderate CYP3A4 inhibitors: dose adjustment
Half-life (t½)	~2–3 hours (terminal elimination half-life)	Short PK half-life but long MR receptor residence time → once-daily dosing is appropriate (see PK-PD Disconnect note below)
Excretion	Urine: ~80% (entirely as metabolites); Faeces: ~20% (as metabolites); <1% excreted unchanged in urine	Parent drug is NOT renally eliminated — dose adjustment in renal impairment is for SAFETY (hyperkalaemia risk due to reduced renal K⁺ excretion), not for drug accumulation
Dialysability	Not expected to be significantly removed by haemodialysis (92% protein-bound; <1% circulates as unchanged parent drug in urine)	No supplemental post-dialysis dose required
Food effect	High-fat, high-calorie meal increases AUC by ~21% and Cmax by ~19%. Low-fat meal has intermediate effect	Recommended: Take with food. Avoid grapefruit/grapefruit juice (CYP3A4 inhibition)
Onset of action	Pharmacodynamic: UACR reduction detectable within 1–4 months. Serum potassium elevation may begin within first 4 weeks (basis for mandatory 4-week potassium check). Haemodynamic: Modest BP reduction (~2–3 mmHg systolic) detectable within weeks. Cardiorenal outcome benefit: accrues over months to years (trial median follow-up: 2.6–3.4 years)	Not an acute-use drug. Patient counselling must set appropriate expectations for time-to-benefit
Duration of action	Sustained MR blockade over 24 hours from a single daily dose (despite ~2–3 hour PK t½)	Once-daily dosing supported by trial evidence
Non-linear PK	Linear pharmacokinetics within the therapeutic dose range (1.25–80 mg studied; 10–20 mg approved)	No dose-dependent PK surprises

Metabolism — Detailed Discussion

Finerenone undergoes extensive hepatic metabolism with negligible renal excretion of unchanged drug.

Primary CYP pathways:

CYP3A4 (~90% of total metabolism): Dominant pathway. Oxidative metabolism of the naphthyridine ring and dihydropyridine moiety. This pathway drives ALL major drug interactions with finerenone:
- ⛔ Strong CYP3A4 inhibitors (itraconazole, ketoconazole, posaconazole, ritonavir, cobicistat, clarithromycin): Increase finerenone AUC up to ~3-fold → concomitant use contraindicated
- ⛔ Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St. John’s Wort): Reduce finerenone AUC by up to ~90% → concomitant use contraindicated (renders drug ineffective)
- ⚠️ Moderate CYP3A4 inhibitors (erythromycin, verapamil, diltiazem, fluconazole, amiodarone): Increase finerenone AUC ~2-fold → concomitant use requires dose adjustment (see Drug Interactions, Part 4)
CYP2C8 (~10% of total metabolism): Minor pathway. Clinically significant interactions via this pathway alone are unlikely. No dose adjustment needed with CYP2C8 inhibitors (e.g., gemfibrozil) based on the small contribution.

Metabolites:

Four primary metabolites have been characterised, designated M1, M2, M3, and M4 in the approved product information. All four are either pharmacologically inactive at the mineralocorticoid receptor or do not achieve clinically relevant plasma concentrations. Unlike spironolactone — which produces the active metabolite canrenone (t½ ~16.5 hours, contributing substantially to prolonged clinical effect) — finerenone’s clinical effect is attributable entirely to the parent compound.

Substrate / Inhibitor / Inducer Status — CYP Enzymes:

CYP Enzyme	Finerenone Status	Clinical Relevance
CYP3A4	Substrate (major)	See interactions above
CYP2C8	Substrate (minor)	Clinically insignificant alone
CYP1A2, 2B6, 2C9, 2C19, 2D6, 3A4	Not an inhibitor or inducer at therapeutic concentrations	Finerenone does NOT alter PK of co-administered drugs via CYP inhibition/induction

💡 Clinical implication: Finerenone is a “victim” drug (its levels are affected by CYP3A4 modulators) but NOT a “perpetrator” (it does not alter levels of other drugs). This simplifies interaction management — the clinician need only assess whether OTHER drugs affect finerenone, not the reverse.

Drug Transporter Pathways

Transporter	Location	Finerenone Status	Clinical Relevance
P-glycoprotein (P-gp / ABCB1)	Intestinal epithelium (apical efflux), hepatic canalicular membrane	Substrate	Co-administration with dual CYP3A4 + P-gp inhibitors (e.g., itraconazole, ritonavir) produces greater AUC increase than CYP3A4 inhibition alone. P-gp inhibition alone has minimal clinical impact
BCRP (ABCG2)	Intestinal epithelium (apical efflux), hepatic canalicular membrane	Substrate	Clinical significance limited at therapeutic doses; no dose adjustment needed with BCRP inhibitors alone
OATP1B1/1B3	Hepatocyte sinusoidal membrane	Not a substrate	Not relevant
OAT1/OAT3	Renal proximal tubule (basolateral)	Not a substrate	Not relevant
OCT2	Renal proximal tubule (basolateral)	Not a substrate	Not relevant
MATE1/MATE2-K	Renal proximal tubule (apical)	Not a substrate	Not relevant
PEPT1/PEPT2	Intestinal/renal epithelium	Not a substrate	Not relevant
OATP2B1	Intestinal epithelium	Not a documented substrate	Not relevant

Finerenone is not an inhibitor or inducer of any of the above drug transporters at clinically relevant concentrations. Therefore, finerenone will not alter the pharmacokinetics of co-administered drugs via transporter-mediated mechanisms.

💡 Practical summary: The only transporter interactions of clinical concern involve finerenone AS A SUBSTRATE of P-gp — and even these are significant only when P-gp inhibition occurs SIMULTANEOUSLY with CYP3A4 inhibition. Isolated P-gp or BCRP inhibition does not warrant dose adjustment.

PK-PD Disconnect: Short Half-Life, Once-Daily Dosing

ℹ️ Key pharmacological concept for prescribers:

Finerenone has a plasma elimination half-life of only ~2–3 hours, yet it is dosed once daily with demonstrated 24-hour efficacy across two large outcome trials (>13,000 patients). This apparent PK-PD disconnect is explained by:

Long mineralocorticoid receptor residence time: After binding, finerenone dissociates very slowly from the MR ligand-binding domain. The receptor occupancy half-life far exceeds the plasma elimination half-life, maintaining effective MR blockade even as plasma drug levels decline to undetectable concentrations.
Genomic (transcription-mediated) mechanism of action: Finerenone’s anti-inflammatory and anti-fibrotic effects are mediated through altered gene transcription — a process measured in hours to days, not minutes. Once the transcriptional programme is initiated by MR blockade, downstream protein expression changes persist well beyond the period of active receptor occupancy.

⛔ Do NOT interpret the short half-life as a reason for twice-daily or more frequent dosing. Once-daily dosing is the ONLY regimen with clinical trial support. No evidence exists that splitting the dose improves efficacy, and splitting may reduce adherence without benefit.

Within-Class Comparison — Mineralocorticoid Receptor Antagonists

⚠️ Finerenone, spironolactone, and eplerenone are NOT interchangeable. No validated dose-conversion ratios exist between these agents. They differ in approved indications, receptor selectivity, diuretic properties, adverse effect profiles, and clinical trial evidence. The following table is provided for comparative pharmacological understanding only — NOT for dose conversion.

Parameter	Finerenone	Spironolactone	Eplerenone
Chemical structure	Non-steroidal (dihydropyridine derivative)	Steroidal (spirolactone ring)	Steroidal (epoxy-substituted)
MR selectivity	Very high (>500-fold over GR, AR, PR)	Low (significant binding to AR, PR → anti-androgenic effects)	Moderate (~100-fold selectivity over GR; minimal AR binding)
Anti-androgenic effects	None	Significant — gynecomastia (6–10%), sexual dysfunction, menstrual irregularity	Minimal
Natriuretic / diuretic effect	None	Yes — acts as potassium-sparing diuretic	Mild
Oral bioavailability	~44% (fasted); ~53% (fed)	~60–73% (extensive first-pass metabolism)	~69%
Active metabolites	None (M1–M4 all inactive)	Yes — canrenone (t½ ~16.5 h, pharmacologically active)	None
PK elimination t½	~2–3 hours	Parent: ~1.4 h; Canrenone: ~16.5 h	~3–6 hours
Pharmacodynamic duration	>24 h (long MR residence time)	>24 h (canrenone contribution)	~12–24 h
Dosing frequency	Once daily	Once or twice daily	Once or twice daily
Cardiac–renal tissue distribution	Balanced (approximately equal)	Kidney-predominant	Kidney-predominant
CYP metabolism	CYP3A4 (90%), CYP2C8 (10%)	CYP3A4, CYP2C8, flavin-containing monooxygenases	CYP3A4 (primary)
Primary CDSCO-approved indications (India)	CKD associated with T2DM	Heart failure, ascites (cirrhosis), refractory hypertension, hyperaldosteronism	Post-MI HF, HFrEF
Key cardiorenal outcome trials	FIDELIO-DKD, FIGARO-DKD, FIDELITY (DKD-specific)	RALES (HFrEF)	EPHESUS (post-MI), EMPHASIS-HF (HFrEF)
NLEM India status	No	Yes	No

⛔ Critical clinical advisory:

Finerenone cannot substitute for spironolactone in heart failure (HFrEF) or cirrhotic ascites — no trial evidence supports this.
Spironolactone cannot substitute for finerenone in diabetic CKD — it was not studied in the FIDELIO/FIGARO populations, and its anti-androgenic adverse effects limit long-term tolerability.
Eplerenone is an alternative to spironolactone in HF (when anti-androgenic effects are intolerable) but has no DKD outcome data.
Prescribe each MRA exclusively for its evidence-supported indication.

Population Pharmacokinetic Notes

Population	PK Change	Clinical Implication
Renal impairment — eGFR 30–59	AUC not significantly altered (parent drug is hepatically metabolised)	Dose adjustment at initiation is for SAFETY (hyperkalaemia risk due to reduced renal K⁺ excretion), NOT for drug accumulation. Start 10 mg OD
Renal impairment — eGFR 15–29	AUC ↑~50% (likely due to reduced hepatic blood flow / general physiological changes in advanced CKD)	Limited trial data (FIDELIO included eGFR ≥25 only). If used, start 10 mg OD with very close potassium monitoring (weekly for first month)
Renal impairment — eGFR <15 or dialysis	No data	⛔ Not recommended — insufficient safety or efficacy data
Hepatic impairment — Child-Pugh A (mild)	AUC ↑~22%	No dose adjustment required; standard potassium monitoring
Hepatic impairment — Child-Pugh B (moderate)	AUC ↑~38%	Use with caution. No formal dose reduction protocol; more frequent potassium monitoring recommended (every 2 weeks for the first 3 months)
Hepatic impairment — Child-Pugh C (severe)	No data	⛔ Avoid — no pharmacokinetic or safety data. Predicted significant accumulation given >90% hepatic metabolism
Elderly (≥60 years)	No clinically significant PK change after adjusting for age-related eGFR decline	Dose selection based on eGFR and potassium, not age per se. Elderly patients are more likely to have lower eGFR → more likely to start at 10 mg
Obesity (BMI >30)	No clinically significant change in AUC or Cmax	No dose adjustment required
Pregnancy	No human PK data	⛔ Contraindicated — animal studies show adverse developmental effects
Paediatric (<18 years)	No PK data	Not approved for paediatric use
Critical illness / ICU	No specific PK data	Hold if patient is unable to take oral medications, is haemodynamically unstable (risk of hyperkalaemia with AKI), or has rapidly changing renal function. Resume when clinically stable and oral intake is possible
Augmented Renal Clearance (ARC)	Not clinically relevant — <1% of parent drug is renally excreted	No dose increase needed in ARC. Unlike renally cleared drugs, finerenone exposure is not significantly affected by high GFR states
Hypoalbuminaemia (cross-cutting modifier)	Finerenone is 92% albumin-bound. In hypoalbuminaemia (serum albumin <3.0 g/dL), free (unbound) drug fraction increases proportionally → enhanced MR occupancy → potentially greater potassium-elevating effect per given dose	Relevant across: nephrotic syndrome, decompensated cirrhosis, critical illness, severe malnutrition, elderly with sarcopenia. Action: More frequent potassium monitoring (every 1–2 weeks during initiation). No formal dose reduction protocol exists; clinical judgment required. Consider starting at 10 mg regardless of eGFR if albumin is significantly low
Pharmacogenomics	CYP3A4: No well-established clinically significant polymorphisms affecting finerenone metabolism. CYP2C8: The CYP2C8*3 allele (reduced function) has an estimated allele frequency of ~3–5% in Indian populations (lower than ~13% in Europeans). Since CYP2C8 contributes only ~10% of finerenone metabolism, even homozygous poor-metaboliser status is unlikely to produce clinically meaningful changes in drug exposure	No pharmacogenomic testing is recommended before starting finerenone

Unique Pharmacological Properties Note: Balanced Cardiorenal Tissue Distribution and Non-Steroidal MR Binding Mode

(Anti-redundancy rule: This is the single, comprehensive discussion of these properties. Cross-referenced in relevant clinical sections; NOT duplicated elsewhere.)

Description and Mechanistic Basis:

Finerenone possesses two pharmacological properties unique among clinically available MRAs:

1. Balanced heart–kidney tissue distribution:

Preclinical studies (rodent models of cardiorenal disease) demonstrate that finerenone distributes approximately equally between cardiac and renal tissue, unlike spironolactone and eplerenone, which concentrate predominantly in the kidney. This balanced distribution is attributed to the drug’s physicochemical profile — moderate lipophilicity, absence of the steroidal scaffold (which drives organic anion transporter–mediated renal concentration of steroidal MRAs), and a molecular geometry that does not preferentially accumulate in renal tubular cells. The clinical implication is that finerenone provides effective MR blockade in BOTH the heart and kidney simultaneously, which may explain its dual cardiorenal benefit in clinical trials.

2. Differential co-regulator recruitment (non-steroidal binding mode):

When finerenone binds the MR, the resulting ligand–receptor conformation is structurally distinct from that induced by steroidal MRAs. This non-steroidal conformation recruits a different repertoire of transcriptional co-regulators (co-activators and co-repressors), resulting in:

More potent suppression of pro-inflammatory gene transcription (NF-κB pathway targets, including MCP-1, PAI-1, and osteopontin)
More potent suppression of pro-fibrotic gene transcription (TGF-β signalling, connective tissue growth factor, collagen types I and III)
Absence of “partial agonist” activity at specific MR-responsive gene promoters — an effect occasionally reported with spironolactone, which can paradoxically upregulate certain MR target genes despite being classified as an antagonist

Clinical Outcome Evidence:

Trial	Reference	N	Population	Primary Endpoint	Result
FIDELIO-DKD	Bakris GL, et al. N Engl J Med. 2020;383:2219–2229	5,674	T2DM with CKD (UACR 30–5000; eGFR 25–75) on optimised RAS blockade	Composite: kidney failure, sustained ≥40% eGFR decline, renal death	HR 0.82 (95% CI 0.73–0.93; p=0.001) — 18% RRR
FIGARO-DKD	Pitt B, et al. N Engl J Med. 2021;385:2252–2263	7,437	T2DM with CKD (UACR 30–5000; eGFR 25–90) on optimised RAS blockade	Composite: CV death, non-fatal MI, non-fatal stroke, HF hospitalisation	HR 0.87 (95% CI 0.76–0.98; p=0.03) — 13% RRR (driven primarily by HF hospitalisation reduction)
FIDELITY (pooled)	Agarwal R, et al. Eur Heart J. 2022;43:474–484	13,026	Combined FIDELIO + FIGARO	Both kidney and CV composites	Confirmed benefits across the full CKD spectrum in T2DM

Clinical Conclusion:

The unique pharmacological properties of finerenone — balanced cardiorenal distribution and non-steroidal MR binding mode — have translated into proven, clinically meaningful kidney AND cardiovascular outcome benefits in patients with CKD associated with T2DM. These properties represent a genuine mechanistic advance over steroidal MRAs. Steroidal MRAs (spironolactone, eplerenone) do NOT have equivalent clinical trial evidence in diabetic CKD, and their benefits in this population should NOT be assumed based on class effect. Finerenone is appropriately positioned as a mechanistically distinct agent specifically indicated for cardiorenal protection in DKD — not as a simple “alternative MRA” to spironolactone or eplerenone.

ADULT INDICATIONS + DOSING

⚠️ Pre-Prescribing Reminder: Finerenone is NOT a diuretic, NOT a primary antihypertensive, and NOT a glucose-lowering agent. It is a cardiorenal organ-protective therapy prescribed specifically to reduce the risk of kidney disease progression and cardiovascular events in the context described below. It is always used as an ADD-ON to optimised renin-angiotensin system (RAS) blockade — never as a substitute for ACEi/ARB, SGLT2 inhibitor, or any antidiabetic therapy.

Primary Indication — Adults (Approved / Standard in India)

INDICATION 1: Reduction of Cardiorenal Risk in Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus (Diabetic Kidney Disease — DKD)

CDSCO-Approved Indication. Finerenone (Kerendia, Bayer Zydus Pharma) is indicated in India to reduce the risk of:

Sustained eGFR decline
End-stage kidney disease (ESKD)
Cardiovascular death
Non-fatal myocardial infarction
Hospitalisation for heart failure

in adults with CKD associated with T2DM.

NLEM Status: ❌ Not included in NLEM India (2022 edition). Not price-controlled by NPPA.

Eligibility Criteria — Mandatory Assessment Before Initiation

Parameter	Requirement	Rationale
Diagnosis	Confirmed T2DM AND CKD (eGFR or albuminuria criteria)	Drug studied exclusively in T2DM-associated CKD
RAS blockade	Patient MUST be on maximally tolerated dose of ACEi OR ARB	⛔ Do NOT start finerenone in a patient NOT on ACEi/ARB — all trial evidence is in the context of background RAS blockade
eGFR	≥25 mL/min/1.73 m²	⛔ Do NOT initiate if eGFR <25 — insufficient safety data
Serum potassium	≤4.8 mEq/L	⛔ Do NOT initiate if K⁺ >4.8 — unacceptable hyperkalaemia risk at baseline
UACR	≥30 mg/g (moderately increased albuminuria or higher)	Trial population had UACR 30–5000 mg/g. No evidence for normoalbuminuric DKD (UACR <30). Prescribing for normoalbuminuric CKD is NOT supported
CYP3A4 interaction check	⛔ No concomitant strong CYP3A4 inhibitors or inducers	Screen medication list BEFORE writing the first prescription (see Drug Interactions, Part 4)
Pregnancy exclusion	Negative pregnancy test if applicable	⛔ Contraindicated in pregnancy

Dosing Algorithm — Decision Tree Format

STEP 1 — SELECT STARTING DOSE (based on baseline eGFR)

Baseline eGFR (mL/min/1.73 m²)	Starting Dose	Rationale
≥60	20 mg once daily with food	Higher eGFR → better renal K⁺ excretory reserve → can tolerate the full dose
25 to <60	10 mg once daily with food	Lower eGFR → reduced renal K⁺ excretory capacity → start at lower dose and titrate
<25	⛔ Do NOT initiate	Insufficient safety and efficacy data. FIDELIO-DKD enrolled patients with eGFR ≥25 only

STEP 2 — FIRST REASSESSMENT AT 4 WEEKS

⚠️ MANDATORY: Check serum potassium AND eGFR at 4 weeks after initiation or ANY dose change.

Serum K⁺ at 4 weeks	Current dose 10 mg	Current dose 20 mg
≤4.8 mEq/L	✅ Increase to 20 mg OD (target maintenance dose)	✅ Continue 20 mg OD
>4.8 to 5.0 mEq/L	⚠️ Maintain 10 mg OD. Do NOT increase. Recheck K⁺ in 4 weeks	⚠️ Maintain 20 mg OD. Recheck K⁺ in 4 weeks
>5.0 to 5.5 mEq/L	⚠️ Withhold finerenone. Address modifiable causes of hyperkalaemia (see below). May restart at 10 mg when K⁺ ≤5.0	⚠️ Reduce to 10 mg OD. Recheck K⁺ within 72 hours to 1 week
>5.5 mEq/L	⛔ WITHHOLD immediately. Manage hyperkalaemia per protocol. May restart at 10 mg only when K⁺ ≤5.0 AND contributing factors corrected	⛔ WITHHOLD immediately. Manage hyperkalaemia per protocol. May restart at 10 mg only when K⁺ ≤5.0 AND contributing factors corrected

STEP 3 — ONGOING DOSE MODIFICATION FOR HYPERKALAEMIA DURING TREATMENT

Use the same K⁺-based algorithm above at EVERY potassium check throughout treatment. Dose changes are bidirectional:

Uptitrate 10 mg → 20 mg when K⁺ ≤4.8 after ≥4 weeks at the lower dose
Downtitrate 20 mg → 10 mg when K⁺ >5.0
Withhold when K⁺ >5.5 or when K⁺ >5.0 and already on 10 mg

Modifiable causes of hyperkalaemia to address BEFORE discontinuing finerenone permanently:

Modifiable Factor	Action
Excessive dietary potassium intake	Dietary counselling (reduce banana, coconut water, potato, spinach, dried fruits, tomato-based dishes)
Potassium supplements	Discontinue or reduce
Potassium-sparing drugs (amiloride, triamterene)	Discontinue
NSAIDs / COX-2 inhibitors	Discontinue if possible (reduce renal K⁺ excretion)
Trimethoprim / cotrimoxazole (regular use)	Switch to alternative antibiotic
Over-dosing ACEi/ARB	Consider modest ACEi/ARB dose reduction (but do NOT discontinue ACEi/ARB to maintain finerenone)
Potassium binder not yet tried	Consider adding sodium zirconium cyclosilicate (SZC, 5–10 g OD) or patiromer (8.4 g OD) to enable continued finerenone use

💡 Clinical tip: The goal is to maintain finerenone at 20 mg OD (the dose with maximum cardiorenal benefit in trials). Every effort should be made to manage hyperkalaemia by addressing modifiable factors and adding potassium binders rather than permanently discontinuing finerenone or accepting 10 mg as the final dose.

STEP 4 — DOSE SUMMARY TABLE

Parameter	Details
Starting dose	10 mg OD (eGFR 25 to <60) or 20 mg OD (eGFR ≥60), with food
Titration	Increase from 10 mg → 20 mg OD at 4 weeks if K⁺ ≤4.8 mEq/L
Usual maintenance dose	20 mg once daily
Maximum dose	Max 20 mg per dose; Max 20 mg per day
Duration	Indefinite — long-term chronic therapy. Continue as long as benefit–risk is favourable. In clinical trials, median treatment duration was 2.6–3.4 years with ongoing benefit accrual
Timing	Once daily with food (any meal). Preferably at the same time each day for adherence. No specific morning vs evening preference — choose timing that best fits patient’s routine

Mandatory Clinical Notes

1. When to Prefer Finerenone Over Alternatives

(a) Clinical scenarios where finerenone has an ADVANTAGE:

Scenario	Advantage of Finerenone	Compared Against
Patient already on optimised ACEi/ARB + SGLT2i who has PERSISTENT albuminuria (UACR ≥30 mg/g) and remains at high cardiorenal risk	Finerenone provides ADDITIVE benefit — further 18% kidney event reduction (FIDELIO) and 13% CV event reduction (FIGARO) ON TOP OF existing RAS blockade ± SGLT2i	No comparator drug provides equivalent additive cardiorenal protection in this residual-risk population
Male patient with DKD who cannot tolerate spironolactone due to gynecomastia or sexual dysfunction	Finerenone has ZERO anti-androgenic effects (no binding to androgen or progesterone receptors)	Spironolactone (gynecomastia incidence 6–10%; sexual dysfunction common)
Patient in whom diuresis is undesirable (euvolaemic, already on loop diuretic + SGLT2i, history of dehydration-related AKI)	Finerenone has NO natriuretic/diuretic effect	Spironolactone (potassium-sparing diuretic effect present)
Patient specifically seeking cardiovascular risk reduction (HF hospitalisation prevention) in DKD context	FIDELITY pooled analysis showed 14% reduction in composite CV events and 22% reduction in HF hospitalisation. No steroidal MRA has DKD-specific CV outcome data	Spironolactone (RALES data is for HFrEF, NOT for DKD); Eplerenone (EPHESUS/EMPHASIS data is for post-MI/HFrEF, NOT for DKD)

(b) Positioning: Finerenone is FIRST-LINE (and currently the only approved) non-steroidal MRA for cardiorenal protection in DKD. It occupies a unique niche — it is NOT first-line for DKD management overall (ACEi/ARB and SGLT2i come first), but it is first-line for the THIRD layer of cardiorenal protection.

(c) Layered Cardiorenal Protection in DKD — Where Finerenone Fits:

Layer	Drug Class	Priority	Evidence
Layer 1 — Foundation	ACEi or ARB (maximally tolerated dose)	MANDATORY before finerenone	RENAAL, IDNT, multiple trials
Layer 2 — Strongly Recommended	SGLT2 inhibitor (dapagliflozin or empagliflozin)	Strongly recommended for ALL DKD patients with eGFR ≥20	CREDENCE, DAPA-CKD, EMPA-KIDNEY
Layer 3 — Additive Benefit	Finerenone (this drug)	Recommended for patients with PERSISTENT albuminuria (UACR ≥30) despite Layers 1 + 2, AND K⁺ ≤4.8	FIDELIO-DKD, FIGARO-DKD
Layer 4 — Additional Benefit	GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide)	Consider for additional CV and weight benefit in T2DM with CKD	SUSTAIN-6, LEADER, REWIND, FLOW

⛔ Finerenone does NOT replace Layers 1 or 2 — it is always ADDITIVE.

ℹ️ Regarding combination with SGLT2 inhibitors: In the FIDELIO and FIGARO trials, only ~6.7% of patients were on a concomitant SGLT2 inhibitor at baseline. Subgroup analyses showed consistent benefit regardless of SGLT2i use. The KDIGO 2024 CKD Guideline endorses using BOTH. From a potassium perspective, SGLT2 inhibitors modestly reduce serum K⁺ (~0.1–0.2 mEq/L), which may partially offset finerenone-induced K⁺ elevation — a pharmacologically favourable pairing.

2. When NOT to Use Finerenone Even Though Technically Indicated

Scenario	Rationale
⛔ Patient NOT on ACEi or ARB (or on subtherapeutic dose without valid reason)	Optimise RAS blockade FIRST. All trial evidence is with background ACEi/ARB
⛔ Baseline K⁺ >4.8 mEq/L	Unacceptable starting hyperkalaemia risk
⛔ eGFR <25 mL/min/1.73 m² (at initiation)	Insufficient data
⛔ Type 1 diabetes	NOT studied. No evidence. Do NOT extrapolate from T2DM data
⛔ Non-diabetic CKD (IgA nephropathy, FSGS, lupus nephritis, ADPKD, etc.)	NOT studied. FIND-CKD trial ongoing but no results yet. Do NOT use outside T2DM-CKD
⛔ Concomitant strong CYP3A4 inhibitor or inducer	Pharmacokinetic contraindication
⛔ Adrenal insufficiency (primary or secondary)	Blocking residual MR activity in a patient with already-deficient aldosterone production → severe hyperkalaemia risk
⚠️ Patient unable to attend regular K⁺ monitoring (e.g., remote rural area without lab access)	Risk of undetected hyperkalaemia outweighs benefit. Consider alternative strategies or ensure telemedicine + local lab access
⚠️ Patient already on spironolactone or eplerenone	Dual MRA therapy is NOT recommended. Choose ONE MRA based on indication: spironolactone for HFrEF/ascites; finerenone for DKD

3. NLEM India Status

❌ Not included in NLEM India (2022 edition). Not price-controlled. Cost is a significant barrier for many Indian patients (see Price Range, Part 5).

4. Typical Time to Expected Clinical Response

Outcome Measure	Expected Timeline
UACR reduction	1–4 months (typically 30–40% reduction from baseline)
Serum potassium rise	Within 4 weeks (basis for mandatory 4-week K⁺ check)
Initial eGFR dip	1–4 months (see detailed note below)
Blood pressure reduction	2–4 weeks (modest: ~2–3 mmHg systolic)
Kidney event reduction	Accrues over months to years. In FIDELIO, Kaplan-Meier curves separated by ~6 months
Cardiovascular event reduction	Accrues over months to years. HF hospitalisation benefit apparent within first year in FIGARO

⚠️ Initial eGFR Dip — Expected Haemodynamic Effect (NOT nephrotoxicity):

Finerenone typically causes an initial eGFR decline of ~2–5 mL/min/1.73 m² within the first 1–4 months. This is a HAEMODYNAMIC effect reflecting reduced intraglomerular pressure and reduced hyperfiltration — the SAME mechanism by which the drug provides long-term kidney protection. This dip is analogous to the well-established “ACEi/ARB dip” and “SGLT2i dip.”

Clinical Situation	Interpretation	Action
eGFR declines by ≤5 mL/min in first 4 months, patient clinically stable, K⁺ manageable	Expected haemodynamic dip	✅ Continue finerenone. This dip is PROTECTIVE, not harmful
eGFR declines by >30% from baseline within first 4 weeks	Concerning — investigate for other causes	⚠️ Hold finerenone. Check for volume depletion, bilateral renal artery stenosis, concurrent nephrotoxin, intercurrent AKI. Resume if reversible cause found and corrected
Rapid eGFR decline with oliguria, hypotension, or clinical deterioration	Likely AKI — NOT a haemodynamic dip	⛔ Stop finerenone. Investigate and manage AKI per standard protocol

ℹ️ Common investigation misconception flag: The initial eGFR dip with finerenone is frequently MISINTERPRETED as drug-induced nephrotoxicity, leading to inappropriate drug discontinuation. Educate patients and referring physicians: “A small drop in kidney function numbers in the first few months is expected and actually shows the medicine is working to protect your kidneys long-term.”

5. Criteria for Considering Treatment Failure and Switching

Situation	Action
Persistent K⁺ >5.5 mEq/L despite withholding finerenone, correcting modifiable factors, and trialling potassium binders	Consider permanent discontinuation. No direct alternative in the ns-MRA class. Ensure Layers 1 and 2 (ACEi/ARB + SGLT2i) are optimised. Add GLP-1 RA for residual cardiorenal risk
eGFR declining rapidly (>5 mL/min/year) despite finerenone, ACEi/ARB, and SGLT2i for >12 months	Finerenone slows but does NOT halt progression. Refer to nephrologist for evaluation of additional causes of CKD progression. Continue finerenone unless discontinuation criteria are met
UACR does not decline at all after 6 months	Assess adherence and verify correct dosing. Rule out secondary causes of persistent albuminuria. Finerenone typically reduces UACR by ~30–40%; non-response is uncommon if drug is taken correctly
Intolerance (other than hyperkalaemia — rare)	No approved alternative ns-MRA in India. Consider spironolactone at low dose (12.5–25 mg) as a class alternative with caution regarding anti-androgenic ADRs. Eplerenone may also be considered but lacks DKD outcome data

6. Mandatory Baseline Investigations Before Starting

Investigation	Status	Rationale
Serum potassium	MANDATORY — must be ≤4.8 mEq/L	Primary safety gatekeeper. Do NOT start if >4.8
eGFR (CKD-EPI)	MANDATORY — must be ≥25 mL/min/1.73 m²	Determines starting dose (10 vs 20 mg) and eligibility
UACR (spot urine)	MANDATORY — must be ≥30 mg/g	Confirms albuminuric DKD (trial population). No evidence for normoalbuminuric CKD
Serum creatinine	MANDATORY (required for eGFR calculation)	—
Medication reconciliation	MANDATORY	Screen for strong CYP3A4 inhibitors/inducers, K⁺-elevating drugs, NSAIDs
Serum albumin	RECOMMENDED	If <3.0 g/dL, expect higher free drug fraction → more frequent K⁺ monitoring
HbA1c	RECOMMENDED	Baseline glycaemic status (finerenone does NOT alter HbA1c, but establishes context for diabetes management)
Blood pressure	RECOMMENDED	Baseline for monitoring modest BP-lowering effect
ECG	OPTIONAL but helpful	If K⁺ is borderline (4.5–4.8), baseline ECG documents pre-treatment T-wave morphology for comparison
Pregnancy test	MANDATORY if applicable	⛔ Contraindicated in pregnancy

7. Specialist Initiation vs Primary Care Prescribing

RECOMMENDED: Specialist initiation by a nephrologist, endocrinologist (diabetologist), or cardiologist experienced in managing DKD.

Rationale:

Requires correct identification of eligible patients (albuminuric DKD on optimised RAS blockade)
Mandatory potassium monitoring schedule with clear escalation/de-escalation algorithm
Interaction with CYP3A4 modulators requires pharmacological awareness
Relatively new drug — clinician familiarity may be limited in primary care

Primary care continuation: Once a patient has been initiated on a stable dose for ≥3 months with two consecutive K⁺ readings ≤5.0 mEq/L, ongoing prescribing and monitoring can be continued by a primary care physician with access to serum potassium testing.

8. Relevant Indian Guideline Sources

Source	Status
RSSDI Clinical Practice Recommendations (2023 update)	Mentions finerenone as an option for cardiorenal protection in DKD, after RAS blockade and SGLT2i
API Textbook of Medicine (latest edition)	Limited coverage; drug is relatively new
KDIGO 2024 CKD Guideline (international, used in Indian nephrology practice)	Recommends finerenone for patients with T2DM, eGFR ≥25, K⁺ ≤4.8, and UACR ≥30, on maximally tolerated RAS blockade. (International source; included because widely adopted by Indian nephrologists)
ICMR	No specific guideline mentioning finerenone as of this edition
AIIMS Protocol	No published finerenone-specific protocol; drug is used at AIIMS Nephrology per KDIGO recommendations

9. Key Disease-Specific Safety Warning

⚠️ HYPERKALAEMIA — Primary Safety Concern

Hyperkalaemia is the most frequent adverse event requiring dose adjustment or drug interruption:

Incidence: Serum K⁺ >5.5 mEq/L occurred in 10.8% (FIDELIO) and 10.8% (FIGARO) of finerenone-treated patients vs 5.3% and 5.3% in placebo groups
Hospitalisation for hyperkalaemia: 1.4% (finerenone) vs 0.3% (placebo) in FIDELIO
Fatal hyperkalaemia: No fatal cases of hyperkalaemia were reported in either trial
Timing: Highest risk in the first 4 months, with continued monitoring needed indefinitely
Risk factors for hyperkalaemia on finerenone:

Risk Factor	Mechanism
Lower baseline eGFR	Reduced renal K⁺ excretory capacity
Higher baseline K⁺ (4.5–4.8)	Less margin before threshold
Concomitant ACEi/ARB (universal)	Additive RAAS blockade
Concomitant potassium supplements	Direct K⁺ load
NSAIDs	Reduce renal K⁺ excretion
Trimethoprim	Blocks ENaC, reduces K⁺ excretion
Dehydration / acute illness	Reduced GFR → reduced K⁺ clearance
Type 4 RTA (hyporeninemic hypoaldosteronism — common in DKD)	Baseline K⁺ handling already impaired
Hypoalbuminaemia	Higher free finerenone fraction → greater MR blockade

⛔ This safety warning must remain with this indication — do NOT defer to Cautions section alone. Potassium monitoring is INTEGRAL to prescribing this drug.

10. Common Clinical Scenarios Where Dose Adjustment Is Needed

Scenario	Action
Patient starts a moderate CYP3A4 inhibitor (e.g., diltiazem, verapamil, erythromycin, fluconazole)	Do NOT formally reduce finerenone dose (no regulatory dose reduction specified), BUT increase K⁺ monitoring frequency (check within 1–2 weeks of CYP3A4 inhibitor initiation). Anticipate ~2-fold increase in finerenone AUC
Patient stops a moderate CYP3A4 inhibitor	Finerenone levels will decrease. No immediate action needed, but if the patient was stable on 10 mg due to previous K⁺ concerns, re-evaluate for uptitration to 20 mg
Acute illness / hospitalisation (fever, vomiting, diarrhoea, sepsis)	⚠️ SICK DAY RULE for finerenone: Hold during acute illness with reduced oral intake, vomiting, diarrhoea, or any condition likely to impair renal function. Resume at previous dose once clinically recovered, oral intake restored, and K⁺ confirmed ≤4.8
eGFR improves from <60 to ≥60 (e.g., after optimising volume status)	If on 10 mg and K⁺ ≤4.8, increase to 20 mg
eGFR declines below 15 during treatment	Consider discontinuation. No trial data supports continued use at eGFR <15
Initiation or uptitration of SGLT2 inhibitor	SGLT2i may modestly reduce K⁺ (~0.1–0.2 mEq/L) — potentially allowing uptitration of finerenone from 10 mg to 20 mg in a patient who was previously borderline. Check K⁺ at 4 weeks
Dose reduction or discontinuation of ACEi/ARB	If ACEi/ARB is reduced/stopped for any reason (e.g., hypotension, AKI), K⁺ may decrease — finerenone can potentially be uptitrated. However, re-assess the indication for finerenone: it should be used WITH RAS blockade. If ACEi/ARB is permanently discontinued, finerenone evidence base no longer directly applies

11. Common Investigation Misconception Flag

ℹ️ Serum creatinine rise in the first 1–4 months is NOT a useful indicator of drug-induced kidney injury with finerenone. The initial haemodynamic eGFR dip (see Clinical Note 4 above) causes a predictable, modest creatinine rise (typically 0.1–0.3 mg/dL) that reflects reduced intraglomerular pressure — the same mechanism that provides long-term nephroprotection. Interpreting this as “worsening kidney function” leads to inappropriate drug discontinuation, depriving the patient of proven cardiorenal benefit.

Rule of thumb: If creatinine rises ≤0.3 mg/dL (or eGFR dips ≤5 mL/min) in the first 4 months, the patient is clinically stable, and K⁺ is manageable → continue finerenone.

12. Dose Escalation Rationale

Not applicable in the traditional dose-escalation sense (finerenone dose is NOT increased beyond 20 mg for this indication). The titration from 10 mg → 20 mg is a SAFETY-GUIDED uptitration — the target dose is always 20 mg, and 10 mg is the cautious starting dose for patients with eGFR <60. The uptitration is gated by serum potassium, not by efficacy assessment.

Secondary Indications — Adults Only (Off-label)

SECONDARY INDICATION 1: Heart Failure with Left Ventricular Ejection Fraction ≥40% (HFmrEF / HFpEF)

⚠️ OFF-LABEL in India — NOT approved by CDSCO for this indication.

ℹ️ Not yet accepted standard practice in India. Include as emerging evidence for specialist decision-making.

Parameter	Details
Indication	Reduction of worsening heart failure events (hospitalisation / urgent HF visit) and cardiovascular death in adults with HF and LVEF ≥40% (NYHA class II–IV), with structural heart disease or elevated natriuretic peptides
Dose	Starting dose: 10 mg OD (if eGFR 25 to <60) or 20 mg OD (if eGFR ≥60); K⁺ must be ≤5.0 mEq/L before initiation
Titration	Uptitrate to 20 mg OD after 4 weeks if K⁺ ≤4.8 (same algorithm as DKD indication)
Maximum dose	Max 20 mg per dose; Max 20 mg per day. ⚠️ Note: In the FINEARTS-HF trial, doses up to 40 mg were used, but the 40 mg strength is NOT commercially available in India. If used off-label, limit to available 10 mg and 20 mg strengths
Duration	Long-term chronic therapy
Specialist only	✅ Cardiologist only — do NOT initiate in primary care
Evidence	Level: Strong (single large RCT)

Evidence basis:

Trial	Reference	N	Primary Endpoint	Result
FINEARTS-HF	Solomon SD, et al. N Engl J Med. 2024;391:1399–1410	6,001	Composite: total worsening HF events + CV death	Rate ratio 0.84 (95% CI 0.74–0.95; p=0.007) — 16% relative risk reduction. Benefit driven primarily by reduction in worsening HF events

Important caveats:

Approximately 50% of FINEARTS-HF participants had T2DM and ~50% did not. Benefit was consistent across diabetic and non-diabetic subgroups — suggesting a class effect for cardiorenal protection beyond DKD.
Dose limitation in India: The trial used a target dose of 40 mg OD (10 → 20 → 40 mg titration). Since 40 mg tablets are NOT available in India, off-label use is limited to 20 mg maximum. Whether the full trial benefit is achievable at 20 mg is uncertain. Subgroup analyses by achieved dose were not separately powered.
Regulatory status: As of this edition, no regulatory agency globally has approved finerenone for heart failure. Approval applications may be pending.
Positioning relative to spironolactone: Spironolactone was studied in HFpEF in the TOPCAT trial (equivocal primary endpoint; regional heterogeneity in results). Finerenone in FINEARTS-HF showed a positive primary endpoint. However, head-to-head comparison does not exist. In HFrEF (LVEF <40%), spironolactone/eplerenone remain the standard MRAs (RALES, EMPHASIS-HF) — finerenone has NOT been studied in HFrEF. ⛔ Do NOT substitute finerenone for spironolactone in HFrEF.
Potassium monitoring: Same protocol as for DKD indication.

SECONDARY INDICATION 2: Non-Diabetic Chronic Kidney Disease

⛔ NOT recommended for off-label use. Included for completeness only.

Parameter	Details
Current status	Under investigation. The FIND-CKD (Finerenone in Non-Diabetic CKD) trial is ongoing. No results available
Evidence level	Very weak — theoretical rationale only (MR overactivation occurs in non-diabetic CKD; anti-inflammatory/anti-fibrotic mechanism is not diabetes-specific)
Clinical action	Do NOT prescribe finerenone for non-diabetic CKD until trial results are available. For non-diabetic CKD, rely on ACEi/ARB + SGLT2 inhibitors (DAPA-CKD, EMPA-KIDNEY included non-diabetic CKD patients)

SECONDARY INDICATION 3: CKD Associated with Type 1 Diabetes

⛔ NOT recommended for off-label use. No clinical evidence exists.

Parameter	Details
Current status	Not studied. Both FIDELIO-DKD and FIGARO-DKD excluded T1DM
Evidence level	Very weak — mechanistic extrapolation only
Clinical action	Do NOT prescribe. T1DM-associated DKD has distinct pathophysiology (predominantly autoimmune, younger patients, different metabolic profile). Await dedicated evidence before considering

MISSED DOSE / DELAYED DOSE GUIDANCE

Dosing frequency: Once daily

Situation	Guidance
Missed dose remembered <12 hours after usual time	Take the missed dose as soon as remembered. Continue next dose at the usual time the following day
Missed dose remembered >12 hours after usual time (i.e., closer to the next day’s dose)	Skip the missed dose. Take the next dose at the usual time. Do NOT double the dose
Single missed dose — risk assessment	A single missed dose is unlikely to cause clinically significant consequences. Finerenone’s long MR receptor residence time means that pharmacodynamic effect persists beyond the drug’s short plasma half-life. There is no acute rebound mineralocorticoid activation from one missed dose
2–3 consecutive missed doses	Resume at the previous dose without re-titration. Check serum potassium at next scheduled visit (no emergency K⁺ check needed unless patient has other reasons for K⁺ instability)
Prolonged non-adherence / drug holiday (>7 days)	Resume at the previous dose. ⚠️ Check serum potassium within 1 week of resumption — the potassium-elevating effect returns with drug resumption, and the previous K⁺ stability data may no longer predict current risk (intercurrent illness, dietary changes, medication changes during the gap may alter K⁺ handling)
Prolonged non-adherence (>4 weeks)	Resume at the STARTING dose based on current eGFR (10 mg if eGFR 25–59, 20 mg if eGFR ≥60). Recheck K⁺ and eGFR at 4 weeks as if initiating the drug anew. This is a precautionary approach because clinical status may have changed significantly during the gap
PRN use	Not applicable — finerenone is a chronic daily medication, not a PRN drug

Rebound / withdrawal effects: No withdrawal syndrome or rebound mineralocorticoid hyperactivation has been documented with finerenone discontinuation. However, abrupt discontinuation removes the anti-inflammatory and anti-fibrotic protection — the cardiorenal benefits are maintained only with continuous use.

Drug holiday and immunogenicity: Not applicable — finerenone is a small-molecule drug, not a biologic.

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

Drug formulation: Oral film-coated tablets (10 mg, 20 mg). No parenteral formulation exists.

Reconstitution: Not applicable — this is an oral solid dosage form.

Administration Notes:

Item	Guidance
Oral administration	Swallow whole with water. Take WITH food (increases bioavailability from ~44% to ~53%)
Crushing / Splitting	⚠️ Manufacturer does NOT recommend crushing, splitting, or chewing. Film-coated formulation; no data on bioavailability of crushed tablets. If patient cannot swallow whole, consult clinical pharmacy for alternative approaches. (Finerenone is NOT an extended-release formulation — crushing would not cause dose-dumping — but stability and bioavailability of crushed tablet are unverified)
Enteral tube administration	No manufacturer data available. If absolutely necessary (hospitalised patient on NG tube who requires continued finerenone), dispersing the tablet in 10–20 mL of water and administering via tube has been used anecdotally. ⚠️ Formulation specification derived from input data — independent verification against Indian product label recommended before clinical use. Flush tube with 20 mL water after administration
Timing	Once daily with any meal. Administer at the same time each day. No morning vs evening preference — choose timing for patient convenience. Avoid grapefruit and grapefruit juice

Weight-Based Dosing Calculation: Not applicable — finerenone is fixed-dose (10 mg or 20 mg), not weight-based.

Stability: Store below 30°C. Protect from moisture. No special light protection required. Shelf life: as per manufacturer’s packaging (typically 24–36 months from manufacturing).

Cold-Chain Requirements: None — finerenone does not require refrigeration. Suitable for standard room-temperature storage across Indian climatic conditions. During extreme summer temperatures (>40°C), store in the coolest available area (inside cupboard/drawer, not near windows or in direct sunlight) but no cold-chain infrastructure is needed.

Storage After Opening: Once the blister pack/strip is opened, use within the manufacturer’s stated shelf life. No reduced shelf-life after opening (unlike liquid formulations or multi-dose containers).

PAEDIATRIC DOSING (Specialist Only)

General Notes

⛔ Finerenone is NOT approved for use in patients <18 years of age by CDSCO or any global regulatory authority.

Parameter	Status
Approved paediatric indication	None
Paediatric clinical trial data	None — no completed paediatric RCTs, pharmacokinetic studies, or dose-finding studies exist
Paediatric PK extrapolation	Not feasible — no paediatric pharmacokinetic modelling has been published. CYP3A4 ontogeny (maturation of expression and activity from infancy through adolescence) would significantly affect drug exposure, but no paediatric PK data exists to guide extrapolation
Suitable paediatric formulation in India	❌ Not available. Only film-coated tablets (10 mg, 20 mg) exist. No liquid, suspension, dispersible tablet, or mini-tablet formulation. Extemporaneous preparation has not been validated
Safety monitoring feasibility in children	Frequent serum potassium monitoring (mandatory for this drug) is feasible in tertiary paediatric centres but poses practical challenges in community paediatric settings

Clinical context: Diabetic kidney disease (the sole approved indication) is overwhelmingly a disease of adults. Type 2 diabetes in children/adolescents is increasing in India but remains relatively uncommon compared to adults, and DKD in paediatric T2DM typically takes years to decades to develop. The clinical scenario requiring finerenone in a paediatric patient is therefore exceedingly rare.

No established paediatric dosing. Use only under specialist supervision in exceptional circumstances — and even then, only after all other evidence-based therapies (ACEi/ARB, SGLT2 inhibitor) have been fully utilised.

Neonatal Dosing

⛔ Not applicable. No neonatal indication exists, no PK data exists, and no clinical scenario warrants neonatal use of finerenone. Diabetic kidney disease does not occur in neonates.

Primary Indications — Paediatric (Approved / Standard in India)

None. No CDSCO-approved paediatric indications exist.

Secondary Indications — Paediatric (Off-label, if any)

None. No off-label paediatric use is supported by evidence or current specialist practice.

⛔ Finerenone should NOT be used in paediatric patients outside a formal clinical trial. If a paediatric nephrologist encounters an exceptional scenario (e.g., adolescent with advanced DKD on maximally tolerated RAS blockade + SGLT2i with persistent high-risk albuminuria), a multidisciplinary discussion with clinical pharmacology input is recommended before considering off-label use. Weight-based dosing cannot be extrapolated from adult fixed-dose data without PK modelling.

RENAL ADJUSTMENT

eGFR Formula Specification

Dosing recommendations for finerenone are based on eGFR calculated by CKD-EPI (2021 creatinine equation), consistent with the FIDELIO-DKD and FIGARO-DKD trial protocols and KDIGO 2024 guidelines.

ℹ️ Note on Cockcroft-Gault CrCl: Unlike DOACs (where Cockcroft-Gault CrCl is the validated formula), finerenone trial data used CKD-EPI eGFR. In most adult patients, the two estimates are concordant. In elderly patients with low muscle mass, CKD-EPI eGFR may overestimate true kidney function relative to Cockcroft-Gault CrCl. When in doubt in elderly/sarcopenic patients, use the lower of the two estimates for conservative dose selection.

Dose Escalation vs Dose Reduction Framing — Critical Distinction

⚠️ Finerenone renal dose adjustment is a MIXED scenario — driven by BOTH safety AND pharmacokinetic considerations, but in an unusual pattern that must be clearly understood:

(a) Safety concern (PRIMARY driver for finerenone):

The dose adjustment in renal impairment is primarily for SAFETY — specifically, hyperkalaemia risk. As eGFR declines, the kidney’s capacity to excrete potassium diminishes. Since finerenone blocks the mineralocorticoid receptor (which normally drives renal K⁺ secretion via ENaC upregulation in the collecting duct), its K⁺-elevating effect is amplified in patients with reduced eGFR.

The parent drug itself does NOT significantly accumulate in renal impairment (<1% renal excretion of unchanged drug).
The dose is reduced at lower eGFR to reduce the intensity of MR blockade and thereby limit K⁺ retention, not to prevent drug accumulation.

(b) NOT an efficacy concern requiring dose escalation:

Unlike loop diuretics (where higher doses are needed in CKD to overcome reduced drug delivery to the tubular lumen), finerenone’s target — the mineralocorticoid receptor — is an intracellular nuclear receptor present in cardiac, vascular, and renal cells. Drug delivery to this receptor depends on systemic plasma concentrations (determined by hepatic metabolism), NOT on renal tubular secretion. Therefore, there is NO pharmacological basis for dose escalation in renal impairment.

💡 Summary for prescribers: In renal impairment, start at a lower dose (10 mg) and titrate up only if potassium permits. The barrier to dose escalation is potassium safety, not drug accumulation.

Renal Dose Adjustment Table

eGFR (mL/min/1.73 m²)	Starting Dose	Titration	Maximum Dose	Potassium Monitoring	MR/ER Formulation Note	Clinical Notes
≥60	20 mg OD	Already at target dose. No uptitration needed	Max 20 mg/dose; Max 20 mg/day	Check K⁺ at 4 weeks, then every 4 months (minimum)	Not applicable — only IR tablets exist	Higher renal K⁺ excretory reserve allows starting at full dose. Hyperkalaemia risk still present — monitoring still mandatory
45 to <60	10 mg OD	↑ to 20 mg OD after 4 weeks if K⁺ ≤4.8	Max 20 mg/dose; Max 20 mg/day	Check K⁺ at 4 weeks post-initiation and 4 weeks post-uptitration, then every 4 months	Not applicable	Moderate CKD. Most patients can successfully uptitrate to 20 mg. K⁺ >4.8 at 4-week check: maintain 10 mg, recheck in 4 weeks
30 to <45	10 mg OD	↑ to 20 mg OD after 4 weeks if K⁺ ≤4.8	Max 20 mg/dose; Max 20 mg/day	Check K⁺ at 4 weeks, then every 2–4 months. Consider more frequent monitoring (monthly) if additional K⁺-elevating risk factors present	Not applicable	Higher hyperkalaemia risk. ~30–40% of patients in this eGFR range may remain on 10 mg long-term due to K⁺ constraints
25 to <30	10 mg OD	↑ to 20 mg OD after 4 weeks if K⁺ ≤4.8	Max 20 mg/dose; Max 20 mg/day	⚠️ Check K⁺ at 2 weeks AND 4 weeks post-initiation/dose change. Then monthly for first 3 months, then every 2–3 months	Not applicable	⚠️ Lower end of trial-studied eGFR range. FIDELIO enrolled patients with eGFR ≥25. Higher vigilance required. Uptitration success rate lower. Consider concomitant potassium binder (SZC or patiromer) prophylactically if K⁺ is 4.5–4.8 at baseline
15 to <25 (non-dialysis)	⚠️ Use NOT recommended	—	—	—	—	Insufficient safety and efficacy data. FIDELIO/FIGARO excluded eGFR <25. If a nephrologist considers use in exceptional circumstances: start 10 mg OD, check K⁺ weekly for first month, do NOT uptitrate to 20 mg. Accept that evidence basis is absent
<15 (non-dialysis)	⛔ Do NOT use	—	—	—	—	No data. Very high hyperkalaemia risk. Residual renal K⁺ excretory capacity insufficient to buffer MR blockade
Haemodialysis	⛔ Do NOT use	—	—	—	—	No trial data in dialysis patients. Inter-dialytic K⁺ fluctuations make safe MR blockade extremely difficult to manage. Finerenone is 92% protein-bound → not significantly removed by HD, so supplemental post-HD dosing is not relevant. The question is whether the drug should be used at all in this population — current answer is NO
Peritoneal dialysis	⛔ Do NOT use	—	—	—	—	No data. Same concerns as haemodialysis. Additionally, peritoneal dialysis patients have less predictable K⁺ clearance than HD patients
CRRT	⛔ Do NOT use	—	—	—	—	CRRT patients are acutely ill with rapidly changing haemodynamics and renal function. Finerenone is a chronic oral therapy not appropriate for this clinical context. Hold and reassess when patient transitions to stable chronic care

Key Clinical Scenarios in Renal Adjustment

Scenario 1: eGFR declines below 25 DURING treatment (patient was started when eGFR was ≥25)

Situation	Action
eGFR declines to 15–24 mL/min/1.73 m² during treatment	The CDSCO product insert and FIDELIO protocol allow CONTINUATION of finerenone at the current dose even if eGFR falls below 25 during treatment — the threshold of 25 applies to INITIATION only. However: ⚠️ increase K⁺ monitoring to every 2–4 weeks. Downtitrate to 10 mg if K⁺ >5.0. Withhold if K⁺ >5.5
eGFR declines to <15 mL/min/1.73 m² during treatment	⚠️ Consider discontinuation. Extremely limited data. If continued by nephrologist decision, K⁺ must be checked weekly. Very high risk of treatment-limiting hyperkalaemia
Patient initiates dialysis during treatment	⛔ Discontinue finerenone when maintenance dialysis is initiated. The cardiorenal protection evidence applies to pre-dialysis CKD

Scenario 2: Acute Kidney Injury (AKI) superimposed on CKD

Situation	Action
Hospitalised with AKI (any KDIGO stage)	⛔ HOLD finerenone immediately. AKI markedly reduces renal K⁺ excretion. Continuing finerenone during AKI creates life-threatening hyperkalaemia risk. Resume only when: (a) AKI has resolved (serum creatinine returned to within 0.3 mg/dL of baseline), (b) K⁺ is ≤4.8, AND © oral intake is reliable
Sick day (vomiting, diarrhoea, dehydration) without frank AKI	⚠️ SICK DAY RULE — HOLD finerenone. Dehydration reduces GFR and K⁺ excretion. Resume when rehydrated and clinically stable. K⁺ check recommended within 1 week of resumption

Scenario 3: Augmented Renal Clearance (ARC)

Not clinically relevant for finerenone. Parent drug is <1% renally excreted. ARC does not increase finerenone clearance and does not require dose increase. Standard dosing applies regardless of high GFR states.

Formulation-Specific Renal Adjustment

Not applicable. Finerenone is available only as immediate-release (IR) film-coated tablets (10 mg, 20 mg). No modified-release (MR), extended-release (ER), or controlled-release (CR) formulations exist. There is no formulation-switching consideration in renal impairment.

Interaction with Renal Adjustment and Concomitant Nephroprotective Agents

This practical table summarises how to manage finerenone dose alongside commonly co-prescribed nephroprotective agents in DKD, all of which affect potassium:

Co-prescribed Agent	Effect on K⁺	Interaction with Finerenone Dosing
ACEi or ARB (mandatory background therapy)	↑ K⁺ (reduced aldosterone-mediated K⁺ secretion)	Additive K⁺-elevating effect. This combination is EXPECTED — all trial participants were on ACEi/ARB. Manage with standard K⁺ monitoring protocol. If hyperkalaemia is persistent, modestly reduce ACEi/ARB dose before discontinuing finerenone (finerenone provides unique cardiorenal benefit not replaceable by higher-dose ACEi/ARB)
SGLT2 inhibitor (dapagliflozin, empagliflozin)	↓ K⁺ (modest, ~0.1–0.2 mEq/L, via osmotic diuresis and natriuresis)	Pharmacologically FAVOURABLE pairing. SGLT2i partially offsets finerenone-induced K⁺ elevation. KDIGO 2024 endorses combined use. Adding SGLT2i to a patient already on finerenone may allow uptitration from 10 mg to 20 mg if K⁺ was previously the limiting factor
Potassium binder (sodium zirconium cyclosilicate / SZC; patiromer)	↓ K⁺ (binds gut K⁺ for faecal excretion)	Enables continued finerenone use in patients with borderline or problematic hyperkalaemia. Consider prophylactic initiation if starting finerenone in a patient with baseline K⁺ 4.5–4.8 and eGFR 25–30
Spironolactone or eplerenone	↑↑ K⁺ (dual MRA blockade)	⛔ Do NOT combine finerenone with another MRA. Dual MRA therapy has no evidence basis and markedly increases hyperkalaemia risk. Choose ONE MRA based on indication
NSAIDs	↑ K⁺ (reduced renal K⁺ excretion + GFR reduction)	⚠️ Strongly avoid concomitant NSAIDs. If short-term NSAID is unavoidable (e.g., post-surgical pain), hold finerenone during NSAID course and check K⁺ before resuming
Trimethoprim / cotrimoxazole	↑ K⁺ (blocks ENaC — structurally similar to amiloride)	⚠️ Avoid regular/prophylactic trimethoprim. If short course needed (3–5 days for UTI), check K⁺ at day 3

HEPATIC ADJUSTMENT

Primary Relevance

Finerenone is >90% hepatically metabolised (CYP3A4 ~90%, CYP2C8 ~10%) with negligible renal excretion of parent drug. Hepatic impairment is therefore expected to significantly increase drug exposure (AUC), potentially leading to enhanced pharmacodynamic effects including greater K⁺ elevation.

Child-Pugh-Based Dose Adjustment

Hepatic Impairment	AUC Change	Dose Adjustment	Potassium Monitoring	Additional Notes
Child-Pugh A (Mild)	AUC ↑~22%	No dose adjustment required. Start per standard eGFR-based algorithm (10 mg or 20 mg)	Standard monitoring: K⁺ at 4 weeks, then every 4 months	Mild increase in exposure is within the range of normal inter-individual variability and is not clinically concerning
Child-Pugh B (Moderate)	AUC ↑~38%	No formal dose reduction protocol from manufacturer. However: ⚠️ Consider starting at 10 mg OD regardless of eGFR and titrating cautiously	⚠️ More frequent K⁺ monitoring: every 2 weeks for first 3 months, then monthly for 3 months, then every 2–3 months thereafter	~38% AUC increase is clinically meaningful. Combined with hypoalbuminaemia common in moderate liver disease (↑ free drug fraction), effective drug exposure at the MR may be substantially higher than in patients with normal hepatic function. Clinical vigilance for hyperkalaemia and hypotension warranted
Child-Pugh C (Severe)	No data (not studied)	⛔ Avoid — no pharmacokinetic or safety data. Predicted significant accumulation given >90% hepatic metabolism	Not applicable — drug should not be used	Severe hepatic impairment likely results in markedly elevated AUC (predicted >2-fold based on metabolic pathway dependence). Additionally, patients with Child-Pugh C cirrhosis often have concurrent hypoalbuminaemia (↑ free drug fraction), ascites (altered Vd), and renal impairment (hepatorenal syndrome) — creating a pharmacokinetically and pharmacodynamically hostile environment for safe MR blockade. These patients should be managed with spironolactone (for ascites, where it is first-line) rather than finerenone

Practical Guidance — When No Formal Hepatic Dosing Data Is Sufficient

For patients with liver disease that does not fit neatly into Child-Pugh categories (e.g., non-cirrhotic fatty liver disease, drug-induced hepatitis, post-hepatitis B/C without cirrhosis):

Clinical Situation	Guidance
NAFLD / NASH without cirrhosis	No dose adjustment required. CYP3A4 activity is generally preserved. Standard eGFR-based dosing. Monitor LFTs at baseline and periodically (every 6 months)
Compensated cirrhosis (Child-Pugh A equivalent)	No dose adjustment. Standard monitoring
Early decompensation (Child-Pugh B equivalent, developing ascites)	Use cautiously at 10 mg OD with frequent K⁺ monitoring (every 2 weeks initially). Note: if ascites is the primary clinical problem, spironolactone (not finerenone) is the indicated MRA — finerenone has NO diuretic/natriuretic effect and will NOT improve ascites
Acute hepatitis (transient elevation of transaminases >3× ULN)	⚠️ Hold finerenone until transaminases normalise or stabilise. Acute hepatocellular injury may transiently impair CYP3A4 activity → unpredictable drug accumulation. Resume at previous dose once LFTs stabilise
Post-liver transplant (on immunosuppressants)	⛔ Extreme caution. Calcineurin inhibitors (tacrolimus, ciclosporin) are CYP3A4 substrates AND inhibitors. Concurrent use may significantly increase finerenone exposure. Additionally, tacrolimus itself causes hyperkalaemia. If considered, specialist hepatology + nephrology + clinical pharmacology input essential. Use lowest dose (10 mg), monitor K⁺ twice weekly initially

Formulation-Specific Hepatic Adjustment

Not applicable. Finerenone is available only as immediate-release (IR) film-coated tablets. No modified-release formulation exists for which first-pass metabolism alterations would create differential risk.

Concurrent Hepatotoxin Note

Concurrent Hepatotoxic Drug	Relevance to Finerenone	Clinical Action
Rifampicin	⛔ CONTRAINDICATED with finerenone — not for hepatotoxicity reasons but because rifampicin is a strong CYP3A4 inducer that reduces finerenone AUC by ~90%, rendering it ineffective. (Hepatotoxicity is a separate concern for the patient’s liver but is not a finerenone-specific interaction)	Do NOT co-prescribe. If anti-TB therapy is required, finerenone must be withheld for the entire duration of rifampicin-containing therapy
Isoniazid	Not a CYP3A4 modulator. Hepatotoxicity risk is INH-specific, not a direct finerenone interaction. However, INH-induced hepatitis may impair CYP3A4 activity and unpredictably alter finerenone metabolism	Monitor LFTs more frequently (monthly) if patient is on both drugs. Hold finerenone if INH-induced hepatitis develops (ALT >5× ULN or >3× ULN with symptoms)
Pyrazinamide	Hepatotoxic; may contribute to transient hepatic impairment during anti-TB treatment. No direct PK interaction with finerenone	Monitor LFTs. Hold finerenone if significant hepatotoxicity develops
Methotrexate	Hepatotoxic with chronic use. No direct CYP-mediated interaction with finerenone	Standard LFT monitoring for methotrexate. No finerenone dose adjustment needed unless hepatic function deteriorates
Valproate	Mild CYP3A4 inhibition (clinically insignificant at standard doses). Hepatotoxic potential (idiosyncratic, rare in adults). No clinically significant interaction with finerenone	No dose adjustment. Standard hepatic and K⁺ monitoring
Antiretrovirals — Protease inhibitors (ritonavir, cobicistat-boosted regimens)	⛔ CONTRAINDICATED with finerenone — ritonavir and cobicistat are potent CYP3A4 inhibitors that increase finerenone AUC ~3-fold	Do NOT co-prescribe. For HIV patients with DKD, use alternative ARV regimens that do not include protease inhibitors or cobicistat-boosted regimens (e.g., dolutegravir-based regimen). Consult HIV specialist for ARV switch
Antiretrovirals — NNRTIs (efavirenz)	Efavirenz is a moderate CYP3A4 inducer. May reduce finerenone exposure (degree not precisely quantified but estimated ~50% reduction)	⚠️ Finerenone efficacy may be compromised. Consider switching to a non-CYP3A4-inducing ARV regimen (e.g., dolutegravir-based). If efavirenz must be continued, finerenone benefit is uncertain
Statins (atorvastatin, rosuvastatin)	Not hepatotoxic in the traditional sense (transaminase elevation is usually benign). No CYP3A4-mediated interaction with finerenone at clinical doses (atorvastatin is a CYP3A4 substrate but not an inhibitor; rosuvastatin is not CYP3A4-dependent)	No finerenone dose adjustment. Continue both drugs with standard monitoring
Paracetamol (chronic high-dose use)	Hepatotoxic at supratherapeutic doses. No PK interaction with finerenone at therapeutic doses	No dose adjustment. Standard advice: paracetamol ≤2 g/day in patients with liver disease

Important Clarification — Finerenone vs Spironolactone in Liver Disease

Clinical Question	Answer
Can finerenone be used for hepatic ascites?	⛔ NO. Finerenone has no diuretic or natriuretic effect. It cannot mobilise ascitic fluid. Spironolactone remains the first-line MRA for cirrhotic ascites (AASLD/EASL/INASL guidelines)
Can finerenone be used in a diabetic CKD patient who also has cirrhosis?	⚠️ Only if the patient’s liver disease is Child-Pugh A and ascites is not the clinical priority. Use 10 mg OD with frequent K⁺ monitoring. If ascites management is needed, use spironolactone for that purpose — but do NOT combine spironolactone + finerenone (dual MRA → severe hyperkalaemia risk)
What if a patient needs both ascites management AND DKD cardiorenal protection?	Use spironolactone for ascites (evidence-based indication). Accept that finerenone-specific DKD benefit will not be achievable simultaneously due to the contraindication of dual MRA therapy. Optimise ACEi/ARB + SGLT2i as the cardiorenal protection strategy in this scenario

CONTRAINDICATIONS

An absolute contraindication means the drug must NEVER be used in this situation — the risk always outweighs any possible benefit.

#	Contraindication	Clinical Rationale
1	⛔ Known hypersensitivity to finerenone or any excipient	Standard pharmacological contraindication. Excipients in Kerendia tablets include: microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate, sodium lauryl sulfate, and film-coating components (including iron oxide pigments). Cross-reactivity with other drugs is not documented (see note below)
2	⛔ Concomitant use with strong CYP3A4 inhibitors	Strong CYP3A4 inhibitors increase finerenone AUC up to ~3-fold → markedly increased MR blockade → unacceptable hyperkalaemia risk. Examples: itraconazole, ketoconazole, posaconazole, voriconazole, ritonavir, cobicistat, nelfinavir, clarithromycin, telithromycin, nefazodone. (Listed in CDSCO product insert as contraindication)
3	⛔ Concomitant use with strong CYP3A4 inducers	Strong CYP3A4 inducers reduce finerenone AUC by up to ~90% → renders drug pharmacologically ineffective → no cardiorenal benefit despite continued pill-taking and monitoring burden. Examples: rifampicin, carbamazepine, phenytoin, phenobarbital, primidone, enzalutamide, mitotane, St. John’s Wort (Hypericum perforatum). While the mechanism is futility rather than toxicity, prescribing an ineffective drug is contraindicated on principle. (Listed as “concomitant use should be avoided” in some regulatory documents; treated as functionally contraindicated in this formulary because there is no clinical benefit)
4	⛔ Concomitant use with another mineralocorticoid receptor antagonist (spironolactone, eplerenone, or any future MRA)	Dual MRA blockade produces additive K⁺ elevation without incremental cardiorenal benefit data. No clinical trial has studied dual MRA therapy. Life-threatening hyperkalaemia is predictable. Choose ONE MRA based on the clinical indication: spironolactone for HFrEF/ascites; finerenone for DKD
5	⛔ Baseline serum potassium >5.0 mEq/L (at initiation)	MR blockade in a patient with pre-existing significant hyperkalaemia → rapid progression to dangerous K⁺ levels. (Note: the CDSCO product insert states “do not initiate if K⁺ >4.8 mEq/L”; some international labels use the >5.0 threshold. This formulary uses the more conservative CDSCO threshold of >4.8 for INITIATION — see Dosing in Part 2 — while listing >5.0 as the absolute contraindication boundary. K⁺ of 4.9–5.0 represents a “near-absolute contraindication” — defer to Cautions)
6	⛔ Addison’s disease (primary adrenal insufficiency)	Patients with Addison’s disease have absent/minimal aldosterone production. Blocking the MR in the context of already-deficient mineralocorticoid activity → profound hyperkalaemia + risk of adrenal crisis. (Not explicitly listed in all product inserts but pharmacologically absolute)

Allergy Cross-Reactivity Note

Finerenone is a non-steroidal compound — a dihydropyridine naphthyridine derivative. Its chemical structure is unrelated to:

Steroidal MRAs (spironolactone, eplerenone) — no cross-reactivity expected
Dihydropyridine calcium channel blockers (amlodipine, nifedipine) — despite sharing the dihydropyridine moiety, the pharmacophores are entirely different and no cross-reactivity has been reported
Sulfonamides — not a sulfonamide-containing drug
Beta-lactams — no structural relationship
NSAIDs — no structural relationship

No drug class-based cross-reactivity has been documented for finerenone. Hypersensitivity, if it occurs, is expected to be drug-specific (to finerenone itself or a tablet excipient) rather than class-based.

CAUTIONS

⚠️ High-Priority Cautions

#	Caution	Risk	Monitoring / Action Required
1	⚠️ Baseline serum K⁺ 4.5–4.8 mEq/L	Higher starting K⁺ → less margin before dangerous hyperkalaemia threshold. FIDELIO subgroup analysis showed numerically higher hyperkalaemia incidence in patients with baseline K⁺ >4.5	Check K⁺ at 2 weeks AND 4 weeks (not just 4 weeks). Start at 10 mg regardless of eGFR. Consider prophylactic potassium binder (SZC or patiromer) at initiation. Ensure dietary potassium counselling before starting
2	⚠️ eGFR 25–29 mL/min/1.73 m² (lower boundary of trial population)	Limited data at the lower extreme of the studied eGFR range. Higher hyperkalaemia risk due to severely impaired renal K⁺ excretion	Start 10 mg OD. Check K⁺ at 2 weeks and 4 weeks. Monthly K⁺ for first 3 months. Do NOT uptitrate to 20 mg unless K⁺ is consistently ≤4.5 at multiple checks
3	⚠️ Concomitant moderate CYP3A4 inhibitor (erythromycin, verapamil, diltiazem, fluconazole, amiodarone, aprepitant)	~2-fold increase in finerenone AUC → enhanced MR blockade → increased K⁺ elevation risk	Start at 10 mg OD regardless of eGFR. Check K⁺ within 1 week of adding or removing the moderate CYP3A4 inhibitor. Do NOT uptitrate to 20 mg unless K⁺ is ≤4.8 after 4 weeks on the combination
4	⚠️ Hypoalbuminaemia (serum albumin <3.0 g/dL)	Finerenone is 92% albumin-bound. Low albumin → ↑ free drug fraction → enhanced pharmacological effect per given dose → greater K⁺ elevation and BP-lowering effect	Conditions: nephrotic syndrome, decompensated cirrhosis, malnutrition, critical illness, elderly sarcopenia. Start at 10 mg OD. Monitor K⁺ every 2 weeks for first 2 months
5	⚠️ Concomitant use with multiple K⁺-elevating agents (ACEi/ARB + potassium supplement + trimethoprim, or ACEi/ARB + NSAID, etc.)	Cumulative K⁺-elevating effects from multiple mechanisms simultaneously	Review and rationalise K⁺-elevating drugs before starting finerenone. Discontinue unnecessary potassium supplements, NSAIDs, regular trimethoprim. ACEi/ARB should be continued (required for finerenone indication) but dose can be modestly reduced if K⁺ is problematic
6	⚠️ Volume depletion or risk of dehydration (active diuresis, hot climate, Ramadan fasting, concurrent SGLT2i, elderly)	Dehydration → ↓ GFR → ↓ renal K⁺ excretion → ↑ hyperkalaemia risk. Also increases risk of symptomatic hypotension	Ensure adequate hydration before starting. Sick day rule applies: hold finerenone during dehydrating illness. In Indian summer months (April–June), counsel patients about increased fluid intake needs
7	⚠️ Type 4 renal tubular acidosis (RTA) / hyporeninemic hypoaldosteronism (common in diabetic CKD)	Baseline K⁺ handling already impaired due to reduced aldosterone secretion and reduced tubular K⁺ excretion. Adding MR blockade further compromises K⁺ elimination	Many DKD patients have subclinical type 4 RTA. If unexplained baseline K⁺ of 4.5–5.0 or episodic hyperkalaemia occurs, suspect type 4 RTA. Start at 10 mg with very close monitoring. Consider concomitant K⁺ binder
8	⚠️ Patients on concomitant calcineurin inhibitors (tacrolimus, ciclosporin) — e.g., kidney transplant recipients	Tacrolimus causes hyperkalaemia (blocks apical K⁺ channels in collecting duct). Ciclosporin inhibits P-gp and weakly inhibits CYP3A4 → may modestly increase finerenone exposure. Combined K⁺-elevating + PK interaction	Specialist supervision only (nephrologist + transplant team). Start 10 mg. K⁺ monitoring twice weekly initially. ⚠️ Note: finerenone has NOT been studied in kidney transplant recipients — use is extrapolated and off-label

Standard Cautions

#	Caution	Notes
1	Hepatic impairment (Child-Pugh B)	~38% increase in AUC. See Hepatic Adjustment (Part 3) for detailed guidance. Not an absolute contraindication but requires more frequent K⁺ monitoring and cautious initiation at 10 mg
2	Symptomatic hypotension or pre-existing low BP (systolic <110 mmHg)	Finerenone produces a modest BP reduction (~2–3 mmHg systolic). While this is generally well-tolerated, patients with pre-existing hypotension or those on multiple antihypertensives may develop symptomatic orthostatic hypotension. Monitor BP at 2 and 4 weeks after initiation
3	Elderly patients (≥60 years) on polypharmacy	Higher likelihood of CYP3A4 interacting drugs, lower baseline eGFR, lower muscle mass (affecting both eGFR estimates and K⁺ buffering), dehydration risk, fall risk from hypotension. See Elderly section below
4	Patients with uncontrolled diabetes (HbA1c >10%)	Uncontrolled hyperglycaemia causes osmotic shifts that can transiently mask hyperkalaemia (intracellular K⁺ shift during acidosis). When glycaemic control is improved (e.g., insulin initiation), K⁺ may rise as extracellular K⁺ redistribution normalises. Monitor K⁺ more frequently during periods of significant glycaemic intervention
5	Planned surgery or procedures	In the perioperative period, renal function may transiently decline (anaesthesia, hypotension, nephrotoxic contrast). Hold finerenone on the morning of surgery. Resume when oral intake is restored, haemodynamics are stable, and K⁺ is confirmed ≤4.8. No mandatory pre-operative washout period (short half-life)
6	Acute illness / intercurrent infection	Sick day rule: hold finerenone during acute illness likely to impair oral intake or renal function (gastroenteritis, severe infection, surgery, dehydration). Resume when recovered
7	Concurrent moderate CYP3A4 inducer (efavirenz, bosentan, modafinil)	May reduce finerenone exposure by ~30–50%. Drug efficacy may be partially compromised. No dose increase above 20 mg is possible with currently available formulations. Consider switching the inducer to a non-inducing alternative if feasible

PREGNANCY

Parameter	Details
Overall safety statement	⛔ CONTRAINDICATED throughout pregnancy.
Former US-FDA category	Not formally categorised under the old A/B/C/D/X system (approved after 2015, when category labelling was discontinued). Functional equivalent: Category X (animal evidence of harm; no human data; risk clearly outweighs any benefit)
Animal teratogenicity data	In animal reproductive studies, finerenone administered to pregnant rats and rabbits at exposures ≥4 times the human AUC at maximum recommended dose (20 mg OD) caused: decreased foetal body weight, delayed ossification, visceral and skeletal variations (rats); increased post-implantation loss (rabbits). No frank structural malformations were observed at tested doses, but the pattern of findings indicates developmental risk
Teratogenicity window	Based on animal data, the greatest risk period appears to be during organogenesis (human equivalent: weeks 3–8 post-conception). However, because finerenone also affects foetal growth (weight reduction), risk extends throughout pregnancy
Trimester-specific risks	First trimester: Highest theoretical teratogenicity risk (organogenesis). Second/third trimester: Foetal growth restriction, potential effects on foetal renal development (MR is expressed in developing kidneys). No human pregnancy exposure data exists to confirm or refute these risks
Human pregnancy data	None. Both FIDELIO and FIGARO excluded pregnant patients and required effective contraception in women of childbearing potential

Pre-conception counselling requirements:

Item	Guidance
Women of childbearing potential	⚠️ Counsel about the need for effective contraception throughout treatment with finerenone. Verify negative pregnancy test before initiation. Recommend reliable contraception (hormonal + barrier, or IUD). Note: finerenone does NOT affect hormonal contraceptive efficacy (it is not a CYP inducer)
Planned pregnancy	Discontinue finerenone before conception. No mandatory washout period (short half-life: ~2–3 hours; drug eliminated within 24 hours of last dose). However, recommend discontinuing at least 1 week before planned conception attempt as a conservative measure
Unplanned pregnancy during treatment	Discontinue finerenone immediately upon pregnancy confirmation. Refer to high-risk obstetric care for foetal monitoring (detailed anomaly scan at 18–20 weeks). No specific antidote or reversal protocol. Counsel the patient that the absolute risk of harm from brief early-pregnancy exposure is uncertain but likely low based on animal data thresholds

Pregnancy Prevention Programme: No formal REMS-type pregnancy prevention programme exists for finerenone (unlike isotretinoin or thalidomide). However, documentation of negative pregnancy test and contraceptive counselling is recommended as standard practice.

Pregnancy Exposure Registry: No dedicated pregnancy exposure registry exists for finerenone as of this edition. Report any inadvertent pregnancy exposure to the manufacturer (Bayer) pharmacovigilance programme and to PvPI.

Preferred alternatives during pregnancy:

Clinical Scenario	Alternative
DKD management during pregnancy	Methyldopa (antihypertensive; pregnancy-safe). ACEi/ARB are ALSO contraindicated in pregnancy — the entire RAAS-blocking strategy must be replaced. Glycaemic control with insulin. Close nephrological and obstetric monitoring. No MRA of any class (spironolactone, eplerenone) is recommended in pregnancy

Fertility Effects:

Sex	Effect
Male fertility	No known effect. Finerenone does NOT bind the androgen receptor → no anti-androgenic effects on spermatogenesis (unlike spironolactone). No human fertility data available, but animal studies at doses up to 10× human AUC showed no adverse effects on male reproductive organs or fertility
Female fertility	No known effect. Finerenone does NOT bind the progesterone receptor. Animal studies at clinically relevant exposures showed no effect on oestrous cycle, mating, or fertility. No human data

LACTATION

Parameter	Details
Compatibility with breastfeeding	⚠️ Use with caution — insufficient data to confirm safety. Not recommended during breastfeeding unless the clinical benefit clearly outweighs the potential risk to the infant
Excretion in breast milk	Unknown in humans. In animal studies (lactating rats), finerenone and/or its metabolites were detected in milk. Given the drug’s moderate lipophilicity and molecular weight (422.5 Da), passage into human breast milk is plausible
Relative Infant Dose (RID)	Not calculated — no human lactation PK data exists
Expected infant exposure	Cannot be estimated. If the drug does pass into milk, the infant would ingest a non-steroidal MRA with the theoretical potential to affect electrolyte handling in the neonatal kidney (immature renal K⁺ excretory capacity → higher hyperkalaemia susceptibility)
What to monitor in infant	If breastfeeding is continued during maternal finerenone use (specialist decision): monitor infant for signs of dehydration, poor feeding, lethargy (potential signs of electrolyte disturbance). Infant serum K⁺ monitoring may be considered if exposure is ongoing
Timing advice	If a single-dose or very short course were needed (not a typical scenario for finerenone, which is chronic therapy): the short half-life (~2–3 h) would allow pump-and-discard for approximately 12–15 hours (5 half-lives) post-dose. However, this is impractical for a drug intended for chronic daily use
Effect on milk production	No data available. MR blockade in mammary tissue has not been studied for finerenone. Spironolactone (steroidal MRA with progesterone receptor activity) has been reported to have galactogenic properties; finerenone lacks progesterone receptor binding and is NOT expected to enhance or suppress milk production

Preferred alternatives during lactation:

No MRA is well-established as safe during lactation. If the patient’s DKD management is the concern:

Continue ACEi (enalapril is the preferred ACEi during lactation — low milk transfer, inactive metabolite)
Continue SGLT2 inhibitor (limited lactation data, but animal data suggests low milk transfer for empagliflozin/dapagliflozin — specialist decision)
Defer finerenone until breastfeeding is completed, accepting a temporary gap in non-steroidal MRA–based cardiorenal protection

Temporary incompatibility guidance: Not applicable in the traditional sense — finerenone is a chronic medication, not a single-dose drug. If a breastfeeding patient has an absolute clinical need for finerenone (specialist decision), the choice is between continuous use with caution (accepting unknown risk to infant) or deferring finerenone until breastfeeding cessation. Pump-and-discard is impractical for chronic daily therapy.

ELDERLY

Definition: For this formulary, elderly = ≥60 years (Indian Census / NPHCE definition).

Recommended Starting Dose

eGFR (mL/min/1.73 m²)	Starting Dose in Elderly	Rationale
≥60	20 mg OD (standard)	If eGFR is preserved and K⁺ ≤4.8, no age-specific dose reduction needed
25 to <60	10 mg OD	Most elderly DKD patients will fall into this category. Standard eGFR-based starting dose
Practical reality in Indian elderly	Most elderly patients with DKD will start at 10 mg OD	Because age-related GFR decline typically places elderly patients in the eGFR 25–59 range. True eGFR ≥60 in elderly DKD patients is uncommon

Titration in Elderly

Parameter	Guidance
Titration speed	Standard — uptitrate to 20 mg at 4 weeks if K⁺ ≤4.8. No specific requirement for slower titration in elderly (drug is already conservatively initiated based on eGFR and K⁺ gating)
Uptitration success rate in elderly	May be lower than in younger adults due to lower eGFR and reduced renal K⁺ excretory reserve. Accept long-term 10 mg dosing if K⁺ does not permit 20 mg

Extra Risks Specific to Elderly

Risk	Details	Action
Hyperkalaemia	Higher baseline risk due to: lower eGFR, type 4 RTA (common in elderly diabetes), polypharmacy (ACEi/ARB, NSAIDs, trimethoprim), reduced dietary variety (lower K⁺ intake may partially offset, but renal excretory capacity is more deterministic)	Monitor K⁺ at 4 weeks and every 3–4 months minimum. Consider every 2 months in the first year. Dietary K⁺ counselling
Hypotension / postural hypotension	Elderly patients often on multiple antihypertensives. Finerenone’s modest BP-lowering (~2–3 mmHg) adds to existing BP-lowering burden. Baroreceptor sensitivity is reduced in elderly → orthostatic tolerance is lower	Measure postural BP at baseline and 4 weeks. If symptomatic orthostatic drop (systolic ≥20 mmHg on standing), reassess overall antihypertensive regimen before attributing to finerenone
Falls	Orthostatic hypotension → fall risk, especially in elderly with neuropathy (diabetic neuropathy is expected in this population), visual impairment, or musculoskeletal comorbidity	Counsel about postural precautions: rise slowly from sitting/lying, hold onto support, avoid sudden position changes. Fall risk assessment at baseline
Dehydration	Elderly have reduced thirst perception, lower total body water, and reduced renal concentrating ability. Concurrent diuretics and SGLT2i (osmotic diuresis) compound dehydration risk. Dehydration → AKI → hyperkalaemia	Adequate fluid intake counselling. Sick day rule awareness. Indian summer heat advisory (Part 2)
Polypharmacy interactions	Elderly diabetic CKD patients are typically on 8–15 medications. Risk of undetected CYP3A4 interaction, K⁺-elevating combination, or NSAID use is higher	Comprehensive medication reconciliation at every visit. Specific CYP3A4 interaction check with each new prescription
Cognitive impairment	Reduced ability to self-manage medications, remember sick day rules, attend monitoring appointments	Involve caregiver/family member in counselling. Consider pill organiser. Written instructions in local language
Sarcopenia / low muscle mass	CKD-EPI eGFR may OVERESTIMATE true kidney function in sarcopenic elderly (low creatinine generation → higher eGFR estimate than actual function). Risk: starting at 20 mg based on falsely reassuring eGFR when true function warrants 10 mg	If clinically sarcopenic or BMI <18.5, consider starting at 10 mg OD regardless of calculated eGFR. Use cystatin C–based eGFR if available for more accurate estimation
QT prolongation risk	Finerenone has NOT been associated with QTc prolongation in dedicated thorough QT studies. However, finerenone-induced hyperkalaemia can cause ECG changes (peaked T waves, widened QRS) that may be confused with QTc changes. Elderly patients on QTc-prolonging drugs (common in polypharmacy) are at risk of additive ECG abnormalities from hypokalaemia correction + QTc drugs	Not a direct finerenone QT risk. ECG at baseline if K⁺ ≥4.5 to document pre-treatment morphology

Beers Criteria / STOPP-START Relevance

Criterion	Relevance to Finerenone
AGS Beers Criteria (2023)	Finerenone is not specifically listed (too new). However, the Beers Criteria flag all MRAs (spironolactone, eplerenone) as “Use with caution in patients with CrCl <30 — risk of hyperkalaemia.” The same caution applies to finerenone. (Frame as additional reference — not primary Indian guidance)
STOPP-START Criteria (v3)	Not specifically listed. STOPP flags “MRAs in patients with K⁺ >5.0 or CKD Stage 4–5 without specialist supervision” — aligns with finerenone prescribing precautions

Anticholinergic Burden

No anticholinergic burden. Finerenone has no anticholinergic properties. It does not bind muscarinic receptors. No contribution to cumulative anticholinergic burden in elderly patients on polypharmacy.

Deprescribing Guidance

Parameter	Guidance
When to consider stopping	(a) eGFR declines to <15 and patient is approaching dialysis → cardiorenal trial benefit no longer clearly applicable. (b) Recurrent life-threatening hyperkalaemia (K⁺ >6.5 or requiring emergency treatment) despite potassium binders + dietary modification. © Patient preference / pill burden in terminal illness context. (d) Drug interactions that cannot be resolved (e.g., newly required strong CYP3A4 inhibitor for fungal infection)
Tapering schedule	Not required. No withdrawal syndrome, no rebound hypokalaemia, no rebound mineralocorticoid activation documented with abrupt discontinuation. Can be stopped immediately without tapering
Expected effects after stopping	K⁺ will normalise within 1–2 days (short drug half-life). Cardiorenal protective effects will wane over weeks to months. UACR may rise back to pre-treatment levels. No acute deterioration expected
Monitoring after stopping	Check K⁺ at 1–2 weeks after stopping (expect normalisation). No further finerenone-specific monitoring needed. Continue monitoring for DKD progression with eGFR + UACR per standard nephrology practice

MAJOR DRUG INTERACTIONS

Interactions classified as MAJOR because they meet at least one criterion: contraindicated combination, life-threatening risk, ≥2-fold AUC change, or mandatory alternative drug selection.

(Cross-reference: Metabolism and transporter pathways described in detail in Pharmacokinetics.)

#	Interacting Drug / Substance	Mechanism	Clinical Effect	Onset Type	Action Required
1	⛔ Itraconazole	Strong CYP3A4 inhibition + P-gp inhibition	Finerenone AUC ↑ ~3-fold (based on PK study with itraconazole 200 mg). Markedly increased MR blockade → severe hyperkalaemia + enhanced hypotension	Acute (within 1–3 days of co-administration)	CONTRAINDICATED. Do NOT co-prescribe. If systemic antifungal is required, use terbinafine (not CYP3A4 inhibitor) or voriconazole at carefully assessed dose (see note below)
2	⛔ Ketoconazole (systemic)	Strong CYP3A4 inhibition + P-gp inhibition	Similar to itraconazole. AUC increase ~3-fold	Acute	CONTRAINDICATED. Topical ketoconazole (shampoo, cream) does NOT produce significant systemic absorption and is SAFE to use with finerenone
3	⛔ Posaconazole	Strong CYP3A4 inhibition	Expected AUC increase ≥3-fold (extrapolated from class effect)	Acute	CONTRAINDICATED
4	⛔ Voriconazole	Strong CYP3A4 inhibition (also a CYP2C19/CYP2C9 inhibitor, but these are not major finerenone pathways)	Expected AUC increase ~2.5–3-fold	Acute	CONTRAINDICATED. ℹ️ For invasive aspergillosis in a patient on finerenone: HOLD finerenone during voriconazole course. Resume finerenone ≥3 days after voriconazole completion (after washout of CYP3A4 inhibitory effect). Check K⁺ before resuming
5	⛔ Ritonavir (including ritonavir-boosted protease inhibitors: lopinavir/r, darunavir/r, atazanavir/r)	Potent CYP3A4 inhibition (ritonavir is used specifically as a pharmacokinetic booster due to its CYP3A4 inhibitory potency)	Finerenone AUC increase ≥3-fold. Life-threatening hyperkalaemia risk	Acute–Gradual (ritonavir has a prolonged inhibitory effect)	CONTRAINDICATED. In HIV patients with DKD, use ARV regimens without ritonavir or cobicistat boosting (e.g., dolutegravir/lamivudine or dolutegravir/tenofovir alafenamide/emtricitabine). Consult HIV specialist for ARV switch
6	⛔ Cobicistat (including cobicistat-boosted regimens: elvitegravir/c, darunavir/c, atazanavir/c)	Potent CYP3A4 inhibition (pharmacokinetic booster; same mechanism as ritonavir)	Finerenone AUC increase ≥3-fold	Acute	CONTRAINDICATED. Same guidance as ritonavir
7	⛔ Clarithromycin	Strong CYP3A4 inhibition	Expected finerenone AUC increase ~2.5–3-fold	Acute	CONTRAINDICATED. Alternative macrolide: azithromycin (NOT a significant CYP3A4 inhibitor — safe to co-prescribe). If H. pylori eradication is needed, use azithromycin-based or non-macrolide regimen
8	⛔ Telithromycin	Strong CYP3A4 inhibition	Expected finerenone AUC increase ≥2.5-fold	Acute	CONTRAINDICATED. Limited availability in India; azithromycin preferred
9	⛔ Nefazodone	Strong CYP3A4 inhibition	Expected finerenone AUC increase ≥2.5-fold	Acute	CONTRAINDICATED. Not widely available in India. Alternative antidepressant: SSRIs (escitalopram, sertraline) have no CYP3A4 inhibitory activity
10	⛔ Rifampicin	Potent CYP3A4 induction (most powerful clinical CYP3A4 inducer)	Finerenone AUC ↓ ~90% (based on PK study). Drug rendered pharmacologically INEFFECTIVE	Gradual (induction effect builds over 1–2 weeks; persists ~2 weeks after rifampicin discontinuation)	CONTRAINDICATED. If anti-TB therapy is required: hold finerenone for the ENTIRE duration of rifampicin-containing treatment (typically 6–9 months). Resume finerenone ≥2 weeks after rifampicin completion (to allow CYP3A4 de-induction). ℹ️ Rifabutin is a moderate CYP3A4 inducer — see Moderate Interactions below
11	⛔ Carbamazepine	Strong CYP3A4 induction (and autoinduction)	Expected finerenone AUC reduction ≥80%. Drug rendered ineffective	Gradual (1–3 weeks to full induction)	CONTRAINDICATED. For epilepsy: switch to a non-inducing AED (levetiracetam, lacosamide, lamotrigine [weak inducer — see Moderate Interactions]). For neuropathic pain: switch to pregabalin/gabapentin (no CYP interactions). For trigeminal neuralgia: consider oxcarbazepine (weaker induction, but still moderate — assess risk-benefit)
12	⛔ Phenytoin / Fosphenytoin	Strong CYP3A4 induction	Expected finerenone AUC reduction ≥80%	Gradual	CONTRAINDICATED. Switch to non-inducing AED
13	⛔ Phenobarbital / Primidone	Strong CYP3A4 induction (primidone is partially metabolised to phenobarbital)	Expected finerenone AUC reduction ≥70–80%	Gradual	CONTRAINDICATED. Switch to non-inducing AED
14	⛔ St. John’s Wort (Hypericum perforatum)	Potent CYP3A4 and P-gp induction	Expected finerenone AUC reduction ≥60–70%. Unpredictable potency due to variable standardisation of herbal preparations	Gradual (1–2 weeks to effect)	CONTRAINDICATED. This is a commonly used herbal supplement in India (“Hypericum” preparations sold OTC). Patients must be specifically asked about herbal supplement use. Traditional medicine interaction
15	⛔ Spironolactone	Dual MRA blockade → additive MR antagonism → compounded K⁺ elevation	Severe hyperkalaemia. No incremental benefit data for dual MRA therapy	Acute (within 1–2 days)	CONTRAINDICATED. Choose ONE MRA. If patient is already on spironolactone for HF → do NOT add finerenone. If DKD cardiorenal protection is the priority and patient does not require spironolactone for HF/ascites → switch from spironolactone to finerenone with ≥48 hours washout (spironolactone’s active metabolite canrenone has t½ ~16.5 h → allow 3–4 days for full washout). Check K⁺ before starting finerenone
16	⛔ Eplerenone	Dual MRA blockade	Same as spironolactone. Additive K⁺ elevation	Acute	CONTRAINDICATED. Choose ONE MRA. Eplerenone washout: 48 hours (t½ ~3–6 h, no long-lived active metabolite)

Food and Herbal Interactions — Major

Substance	Mechanism	Clinical Effect	Action
⛔ St. John’s Wort	See #14 above	See above	See above — CONTRAINDICATED
⚠️ Grapefruit juice (large quantities, >1 litre/day)	CYP3A4 inhibition in intestinal wall → increased oral bioavailability	May increase finerenone AUC by ~50–100% (estimated from class effect of grapefruit on CYP3A4 substrates; no dedicated grapefruit-finerenone PK study)	Small amounts (a glass of juice, occasional fruit) are unlikely to produce clinically significant effects. ⚠️ Avoid regular large-quantity consumption. Counsel patients: “Avoid drinking large amounts of grapefruit juice (mosambi/chakotra juice) daily while taking finerenone”
⚠️ Ashwagandha (Withania somnifera) — commonly used in India	Limited data. Some in vitro evidence suggests weak CYP3A4 inhibition. Clinical significance unknown	Theoretical increase in finerenone exposure (magnitude uncertain)	Traditional medicine interaction. Ask patients about Ashwagandha/Ashwagandha-containing supplements. If used regularly, monitor K⁺ more frequently. Data limited — cannot definitively classify as safe or unsafe
⚠️ Turmeric / Curcumin supplements (high-dose)	In vitro CYP3A4 inhibition at high concentrations; clinical significance of dietary turmeric is negligible, but concentrated curcumin supplements (500–1000 mg/day) may achieve inhibitory concentrations	Possible modest increase in finerenone exposure	Traditional medicine interaction. Dietary turmeric in food (haldi in cooking) is safe. ⚠️ High-dose curcumin SUPPLEMENTS should be used with caution — monitor K⁺ if patient is taking >500 mg/day curcumin supplements

MODERATE DRUG INTERACTIONS

Interactions that usually permit co-prescription but require monitoring, dose adjustment, or clinical vigilance.

#	Interacting Drug / Substance	Mechanism	Clinical Effect	Onset Type	Action Required
1	⚠️ Erythromycin	Moderate CYP3A4 inhibition	Finerenone AUC ↑ ~2-fold	Acute	Start finerenone at 10 mg OD regardless of eGFR when co-prescribed with erythromycin. Check K⁺ within 1 week of starting the combination. If erythromycin is a short course (5–7 days): holding finerenone during the course is an alternative approach. Preferred alternative: azithromycin (no CYP3A4 interaction)
2	⚠️ Verapamil	Moderate CYP3A4 inhibition + weak P-gp inhibition	Finerenone AUC ↑ ~2-fold. Additionally, verapamil itself has negative inotropic and chronotropic effects	Acute–Gradual	Start finerenone at 10 mg OD regardless of eGFR. Check K⁺ within 1–2 weeks. Monitor BP (additive hypotensive effect). If uptitrating to 20 mg, check K⁺ at 2 and 4 weeks. ℹ️ Verapamil is commonly used in Indian practice for rate control in AF and hypertension. If the patient requires a CCB, amlodipine or nifedipine (dihydropyridine CCBs — NOT CYP3A4 inhibitors) are preferred alternatives
3	⚠️ Diltiazem	Moderate CYP3A4 inhibition	Finerenone AUC ↑ ~2-fold	Acute–Gradual	Same action as verapamil. Start finerenone at 10 mg. Preferred alternative CCB: amlodipine (no CYP3A4 interaction)
4	⚠️ Fluconazole (200–400 mg/day)	Moderate CYP3A4 inhibition (dose-dependent; also strong CYP2C9 and CYP2C19 inhibitor, but these are not major finerenone pathways)	Finerenone AUC ↑ ~1.5–2-fold (estimated)	Acute	Start finerenone at 10 mg OD regardless of eGFR. If fluconazole is a short course (single dose for vaginal candidiasis = 150 mg × 1): no finerenone adjustment needed (single-dose exposure insufficient to significantly alter finerenone PK). For courses ≥3 days at ≥200 mg: check K⁺ within 1 week
5	⚠️ Amiodarone	Moderate CYP3A4 inhibition + P-gp inhibition. Extremely long t½ of amiodarone (~40–55 days) → inhibitory effect persists for WEEKS after amiodarone discontinuation	Finerenone AUC ↑ ~1.5–2-fold. Effect persists long after amiodarone is stopped	Gradual onset, VERY gradual offset	Start finerenone at 10 mg OD regardless of eGFR in patients on amiodarone. Check K⁺ within 1 week. ⚠️ If amiodarone is discontinued, continue treating finerenone as if the interaction persists for ≥8 weeks (amiodarone washout is extremely slow). Uptitrate finerenone only after ≥8 weeks post-amiodarone and K⁺ check
6	⚠️ Aprepitant / Fosaprepitant	Moderate CYP3A4 inhibition (aprepitant is a moderate inhibitor for 2–3 days post-dose; fosaprepitant is its IV prodrug)	Transient finerenone AUC increase during antiemetic course	Acute (short-duration)	If receiving aprepitant as part of chemotherapy antiemetic regimen (typically 3-day course): hold finerenone during the aprepitant course and resume 2 days after last aprepitant dose. Check K⁺ before resuming
7	⚠️ Cimetidine	Weak–moderate CYP3A4 inhibition + renal tubular cation transport inhibition	Modest finerenone exposure increase (~1.3-fold estimated). Clinically marginal	Acute	No dose adjustment. Standard K⁺ monitoring. ℹ️ Cimetidine use is declining in India (PPIs preferred), but may be encountered in older patients. Ranitidine and famotidine do NOT inhibit CYP3A4 — no interaction
8	⚠️ Efavirenz	Moderate CYP3A4 induction	Finerenone AUC ↓ ~30–50% (estimated). Drug efficacy may be compromised	Gradual (1–2 weeks)	Finerenone may be less effective. If HIV-DKD patient requires finerenone, consider switching to a non-inducing ARV (dolutegravir-based regimen is preferred and does NOT induce CYP3A4). If efavirenz must be continued, use finerenone 20 mg OD (maximum available dose) and accept that efficacy may be suboptimal. No dose above 20 mg is possible with current formulations
9	⚠️ Bosentan	Moderate CYP3A4 induction	Finerenone AUC ↓ ~30–40% (estimated)	Gradual	Similar concern as efavirenz. If patient requires endothelin receptor antagonist (e.g., for pulmonary hypertension) + finerenone for DKD: use finerenone 20 mg and accept possible reduced efficacy. Consider ambrisentan as alternative (weaker CYP3A4 induction)
10	⚠️ Rifabutin	Moderate CYP3A4 induction (weaker than rifampicin)	Finerenone AUC ↓ ~40–50% (estimated from class effect)	Gradual	⚠️ Preferred over rifampicin if anti-TB regimen is needed in a patient on finerenone — but finerenone efficacy may still be compromised. Use finerenone 20 mg OD and accept suboptimal exposure. ℹ️ Rifabutin is NOT widely available in India and is primarily used in MDR-TB or TB-HIV co-infection
11	⚠️ ACEi (enalapril, ramipril, lisinopril, etc.)	Pharmacodynamic: additive RAAS blockade → additive K⁺ elevation	K⁺ elevation is EXPECTED and MANAGED — this is not a reason to avoid the combination. All FIDELIO/FIGARO participants were on ACEi or ARB	Gradual (weeks)	Expected co-prescription. This is NOT a “problem” interaction — it is the intended clinical context. Monitor K⁺ per standard finerenone protocol. If K⁺ becomes problematic, modestly reduce ACEi dose before discontinuing finerenone (finerenone provides cardiorenal benefit beyond ACEi alone)
12	⚠️ ARB (losartan, telmisartan, olmesartan, etc.)	Same as ACEi	Same as ACEi	Gradual	Same as ACEi. ℹ️ Do NOT combine ACEi + ARB + finerenone (triple RAAS blockade). Use ACEi OR ARB (not both) + finerenone
13	⚠️ NSAIDs (ibuprofen, diclofenac, naproxen, etc.) and COX-2 inhibitors (etoricoxib, celecoxib)	Pharmacodynamic: NSAIDs reduce renal prostaglandin synthesis → ↓ GFR → ↓ renal K⁺ excretion → additive K⁺ elevation with finerenone. Also increase AKI risk (“triple whammy” with ACEi/ARB)	Significant hyperkalaemia risk, especially with regular NSAID use	Acute (within days of regular NSAID use)	⚠️ Avoid concomitant regular NSAID use. If short-term NSAID is unavoidable (e.g., 3–5 days for acute pain), hold finerenone during the course and check K⁺ before resuming. For chronic pain in DKD patients: paracetamol is preferred; low-dose tramadol or pregabalin/duloxetine for neuropathic pain
14	⚠️ Trimethoprim / Co-trimoxazole (TMP-SMX)	Trimethoprim blocks ENaC in collecting duct (structurally similar to amiloride) → ↓ renal K⁺ secretion → additive K⁺ elevation with finerenone	Clinically significant hyperkalaemia, especially at high TMP doses or in CKD	Acute (within 2–3 days)	⚠️ Avoid regular/prophylactic TMP-SMX in patients on finerenone. If short course needed for UTI (3–5 days): check K⁺ at day 3. If K⁺ >5.0, hold finerenone until TMP course completed and K⁺ normalised. Alternative antibiotics for UTI: nitrofurantoin (if eGFR >30), fosfomycin, amoxicillin-clavulanate (based on sensitivity)
15	⚠️ Potassium supplements (KCl, potassium citrate)	Direct addition of K⁺ load in a patient with pharmacologically reduced K⁺ excretion	Hyperkalaemia	Acute	Discontinue or significantly reduce potassium supplements before starting finerenone. If K⁺ supplementation was needed for loop diuretic–induced hypokalaemia, reassess after finerenone initiation (MR blockade will raise K⁺ independently). Monitor K⁺ closely if supplements must be continued
16	⚠️ Potassium-containing salt substitutes (e.g., “Lo Salt,” potassium chloride–based table salt alternatives)	Dietary K⁺ load	Additive hyperkalaemia risk	Acute	Counsel patients to STOP using potassium-based salt substitutes. Regular table salt (NaCl) in moderation is preferred to K⁺-containing substitutes in patients on finerenone
17	⚠️ Heparin / LMWH (prolonged use >7 days)	Heparin suppresses adrenal aldosterone synthesis → reduced endogenous K⁺ excretion → additive effect with MR blockade	Hyperkalaemia (usually significant only with prolonged heparin courses, e.g., therapeutic anticoagulation for >1 week)	Gradual (days)	If prolonged heparin is needed (e.g., bridge anticoagulation, HIT treatment): check K⁺ at day 3 and day 7. Brief prophylactic-dose LMWH (e.g., perioperative 3–5 days) is unlikely to produce significant interaction
18	⚠️ Tacrolimus	Pharmacodynamic: tacrolimus causes hyperkalaemia (blocks apical K⁺ channels in collecting duct, suppresses aldosterone). Pharmacokinetic: tacrolimus is a CYP3A4 substrate — no PK effect ON finerenone; but ciclosporin (see below) differs	Additive K⁺ elevation + both drugs cause K⁺ retention by different mechanisms	Gradual	Specialist use only (transplant nephrology). Finerenone is NOT studied in transplant recipients. If considered off-label: use 10 mg OD maximum, K⁺ monitoring twice weekly initially
19	⚠️ Ciclosporin	P-gp inhibition (strong) + weak CYP3A4 inhibition + pharmacodynamic K⁺-elevating effect (ciclosporin causes hyperkalaemia via vasoconstriction of afferent arteriole + tubular effects)	Possible modest increase in finerenone exposure + additive K⁺ elevation	Gradual	⚠️ Same guidance as tacrolimus — specialist only, 10 mg OD maximum, very close K⁺ monitoring. Not studied
20	⚠️ Digoxin	NOT a pharmacokinetic interaction. Pharmacodynamic: finerenone-induced hyperkalaemia REDUCES digoxin toxicity risk (K⁺ competes with digoxin for Na/K-ATPase binding). HOWEVER, finerenone-induced K⁺ changes make digoxin toxicity threshold less predictable	Altered digoxin toxicity threshold. ℹ️ This is actually a PROTECTIVE interaction in the hyperkalaemia direction — but rapid K⁺ changes in either direction destabilise digoxin-K⁺ equilibrium	Gradual	Monitor K⁺ and digoxin levels more frequently when finerenone is started, stopped, or dose-changed in a patient on digoxin. Maintain K⁺ in the 4.0–5.0 range for optimal digoxin safety

COMMON ADVERSE EFFECTS

Adverse effects occurring in ≥1% of finerenone-treated patients in FIDELIO-DKD and/or FIGARO-DKD trials.

Metabolic / Electrolyte

Adverse Effect	Frequency Band	Incidence (Finerenone vs Placebo)	Dose-Dependent?	Transient?	Clinical Notes
Hyperkalaemia (investigator-reported AE)	Very common (≥10%)	15.8% vs 7.8% (FIDELIO); 10.8% vs 5.3% (FIGARO)	Yes — higher incidence at 20 mg vs 10 mg, and in lower eGFR categories	No — ongoing risk throughout treatment. Highest in first 4 months but continues	See Signature ADR in Serious Adverse Effects below for detailed management. Most cases are mild-moderate (K⁺ 5.1–5.5) managed with dose adjustment
Hyponatraemia (serum Na⁺ <135 mEq/L)	Common (1–10%)	1.2% vs 0.6% (FIDELIO)	Data limited	Usually mild and asymptomatic	Monitor serum sodium periodically. Clinically significant hyponatraemia (<125 mEq/L) was rare (<0.5%)

Cardiovascular

Adverse Effect	Frequency Band	Incidence	Dose-Dependent?	Transient?	Clinical Notes
Hypotension / decreased blood pressure	Common (1–10%)	4.8% vs 3.4% (FIDELIO); 5.3% vs 4.0% (FIGARO)	Modest dose-response	May be transient in early weeks; persistent if on multiple antihypertensives	Usually symptomatic only in patients with pre-existing low BP or on multiple antihypertensive agents. Average systolic BP reduction: ~3 mmHg

Renal

Adverse Effect	Frequency Band	Incidence	Dose-Dependent?	Transient?	Clinical Notes
eGFR decrease (haemodynamic dip)	Very common (≥10%) — as a LABORATORY finding; infrequently reported as a clinical AE	~2–5 mL/min decline in first 4 months in most patients	Not significantly dose-dependent	Stabilises after 4 months; long-term eGFR slope is BETTER with finerenone vs placebo	⚠️ This is a PHARMACOLOGICAL EFFECT, not an adverse event (see detailed discussion in Part 2, Clinical Note 4). However, it may be coded as an AE in clinical practice and regulatory reports. Educate clinicians not to reflexively discontinue finerenone for this expected dip

Other

Adverse Effect	Frequency Band	Incidence	Clinical Notes
Pruritus	Common (1–10%) — reported in some post-marketing data	~1–2% (limited data)	Mild, not typically requiring discontinuation. Manage with emollients. No relationship to anti-androgenic effects (absent with finerenone)
Dizziness	Common (1–10%)	~1–3%	Related to hypotension. Positional. More common in elderly

💡 Notable ABSENCE of adverse effects seen with steroidal MRAs:

Adverse Effect	Spironolactone	Finerenone	Explanation
Gynecomastia / breast tenderness	6–10%	0% (no cases reported)	Finerenone has NO androgen receptor binding
Sexual dysfunction (male)	3–8%	Not reported	Same — no anti-androgenic effect
Menstrual irregularity	Common at doses ≥100 mg/day	Not reported	Finerenone has NO progesterone receptor binding
Deepening of voice	Uncommon but reported	Not reported	No androgenic or anti-androgenic effect

SERIOUS ADVERSE EFFECTS

⚠️ Signature ADR: HYPERKALAEMIA — Finerenone-Specific

This is the primary serious adverse effect requiring detailed management guidance. It is the most common reason for dose adjustment, drug interruption, and drug discontinuation in clinical trials.

Parameter	Data
Classification	⚠️ Signature ADR — occurs at significantly higher incidence than placebo and is the dose-limiting toxicity of all MRAs. However, finerenone-associated hyperkalaemia is predictable, monitorable, and manageable with the K⁺-gated dosing algorithm
Incidence — any hyperkalaemia (K⁺ >5.5 mEq/L)	FIDELIO: 21.7% vs 9.8% (lab values); FIGARO: 14.2% vs 6.9%
Incidence — K⁺ >6.0 mEq/L	FIDELIO: 4.5% vs 1.4%; FIGARO: 1.5% vs 0.5%
Hospitalisation for hyperkalaemia	FIDELIO: 1.4% vs 0.3%; FIGARO: 0.6% vs 0.1%
Drug discontinuation due to hyperkalaemia	FIDELIO: 2.3% vs 0.9%; FIGARO: 1.7% vs 0.6%
Fatal hyperkalaemia	ZERO cases in either trial (>13,000 patients combined). This is noteworthy — while hyperkalaemia is common, the K⁺-gated dosing algorithm prevented fatal outcomes
Timing	Highest risk: first 4 months (particularly weeks 4–16). Continues throughout treatment at lower incidence. Any intercurrent illness, dehydration, or medication change can trigger new episodes
Mechanism	MR blockade in the renal collecting duct reduces ENaC-mediated Na⁺ reabsorption and coupled K⁺ secretion. Additionally, MR blockade in the distal convoluted tubule and connecting segment reduces ROMK channel activity. Net effect: reduced renal K⁺ excretion. Concurrent ACEi/ARB further reduces aldosterone-driven K⁺ secretion → compounding effect

Risk Factors for Hyperkalaemia on Finerenone:

Risk Factor	Estimated Relative Risk Increase
Lower baseline eGFR (25–30 vs >60)	~2-fold
Higher baseline K⁺ (4.5–4.8 vs <4.0)	~1.5–2-fold
Concomitant moderate CYP3A4 inhibitor	~1.5-fold (increased drug exposure)
Concomitant NSAIDs	Significant (not precisely quantified)
Concomitant trimethoprim	Significant
Concomitant potassium supplements	Significant
Hypoalbuminaemia (albumin <3.0)	Likely increased (theoretical — higher free drug fraction)
Type 4 RTA (common in DKD)	Increased (baseline K⁺ handling impaired)
Dehydration / volume depletion	Significantly increased (↓ GFR → ↓ K⁺ clearance)
Acute illness / hospitalisation	Significantly increased

Management Protocol for Hyperkalaemia on Finerenone:

STEP 1 — Confirm and Classify

Serum K⁺	Severity	ECG Changes?	Clinical Symptoms?
5.1–5.5 mEq/L	Mild	Typically none	None
5.6–6.0 mEq/L	Moderate	Possible peaked T waves	Usually none; check for muscle weakness
6.1–6.5 mEq/L	Severe	Peaked T waves, possible PR prolongation	Possible weakness, paraesthesiae
>6.5 mEq/L	Life-threatening	Widened QRS, sine wave pattern, VF risk	Weakness, paralysis, cardiac arrest risk

STEP 2 — Acute Management (K⁺ >5.5 with ECG changes or K⁺ >6.0)

Intervention	Dose	Onset	Duration	Available in India?
Calcium gluconate 10% IV (cardiac membrane stabilisation — does NOT lower K⁺)	10 mL IV over 2–3 minutes. May repeat once if ECG abnormalities persist	1–3 minutes	30–60 minutes	✅ Widely available
Insulin + Glucose (intracellular K⁺ shift)	Regular insulin 10 units IV + 25 g dextrose (50 mL of 50% dextrose)	15–30 minutes	4–6 hours	✅ Widely available
Nebulised salbutamol (intracellular K⁺ shift)	10–20 mg via nebuliser	15–30 minutes	2–4 hours	✅ Widely available
Sodium bicarbonate 8.4% IV (intracellular K⁺ shift — efficacy debated; most useful if concurrent metabolic acidosis)	50 mEq IV over 5 minutes	15–60 minutes	2 hours	✅ Available
Sodium polystyrene sulfonate (Kayexalate) or Sodium zirconium cyclosilicate (SZC) (K⁺ removal via gut)	SZC: 10 g × 3/day for 48 hours; Kayexalate: 15–30 g oral or rectal	1–6 hours	Until K⁺ normalises	✅ Kayexalate widely available. SZC (Lokelma) available in metros — limited availability
Patiromer (K⁺ removal via gut)	8.4 g OD	7+ hours (slower onset than SZC)	Chronic use	✅ Available (Veltassa) — metro/urban availability
Haemodialysis (definitive K⁺ removal)	—	Immediate during session	Duration of session	For refractory or life-threatening cases

STEP 3 — Finerenone Dose Action

(See detailed K⁺-gated dosing algorithm in Step 2)

K⁺ Level	Finerenone Action
5.1–5.5	Withhold if on 10 mg. Reduce 20 mg → 10 mg. Recheck K⁺ in 72 hours–1 week
>5.5	WITHHOLD immediately. Address modifiable factors. Resume at 10 mg only when K⁺ ≤5.0 AND contributing factors corrected
>6.5 or ECG changes	WITHHOLD immediately. Acute management per protocol above. Consider whether finerenone can be safely restarted at ALL — assess risk-benefit with specialist input

Recurrence / Re-challenge Policy:

Scenario	Re-challenge Decision
Single episode K⁺ 5.1–5.5, clear precipitant identified and corrected (e.g., dehydration, NSAID, dietary indiscretion)	✅ Re-challenge at 10 mg after K⁺ normalises. Can attempt re-titration to 20 mg after 4 weeks if K⁺ permits
Single episode K⁺ >5.5, clear precipitant identified and corrected	⚠️ Re-challenge at 10 mg with close monitoring (K⁺ at 1, 2, and 4 weeks). Do NOT re-titrate to 20 mg for at least 3 months
Recurrent episodes (≥2) of K⁺ >5.5 despite potassium binder + dietary modification + dose reduction to 10 mg	⚠️ Consider permanent discontinuation. The patient may not tolerate MR blockade at any dose. Optimise other cardiorenal therapies (ACEi/ARB + SGLT2i + GLP-1 RA)
Any episode of K⁺ >6.5 requiring emergency treatment	⛔ Strong consideration for permanent discontinuation unless a clear, correctable precipitant was unequivocally identified (e.g., inadvertent potassium infusion, NSAID initiation by another prescriber)

Cross-reactivity implications: Hyperkalaemia is a CLASS EFFECT of all MRAs (spironolactone, eplerenone, finerenone). If a patient develops treatment-limiting hyperkalaemia on finerenone, switching to spironolactone or eplerenone will NOT solve the problem — the same K⁺-elevating mechanism applies. The option is to discontinue MRA therapy entirely or to use potassium binders more aggressively.

Other Serious Adverse Effects

Adverse Effect	Frequency	Mechanism	Management	Requires Discontinuation?
Symptomatic hypotension / syncope	Uncommon (<1%)	Additive BP-lowering in patients on multiple antihypertensives. Exacerbated by volume depletion	Assess volume status. Reduce other antihypertensives first. IV fluids if hypovolaemic. Finerenone contributes ~2–3 mmHg systolic reduction — other agents are more likely the primary cause	Not usually. Hold temporarily if symptomatic; resume when stable
Acute kidney injury	Uncommon (<1%) — as a serious AE requiring hospitalisation	Usually precipitated by volume depletion, concurrent nephrotoxin, or intercurrent illness — NOT a direct nephrotoxic effect of finerenone	Standard AKI management. Hold finerenone during AKI. Resume when renal function recovers to within 0.3 mg/dL of baseline creatinine	Hold during AKI. Resume when resolved
Hepatotoxicity	Very rare — no clear signal in clinical trials	Unknown. Finerenone is hepatically metabolised but has not been associated with idiosyncratic hepatotoxicity	If unexplained ALT >3× ULN: hold and investigate. No rechallenge guidance available (insufficient data). Report to PvPI	Hold and investigate. Report to PvPI

⚠️ PvPI Reporting: For all serious adverse effects (hyperkalaemia requiring hospitalisation, symptomatic hypotension/syncope, AKI, hepatotoxicity, or any unexpected serious event): Report to the nearest ADR Monitoring Centre under the Pharmacovigilance Programme of India (PvPI) or via the ADR reporting form on the CDSCO website (https://www.cdsco.gov.in). Finerenone is a relatively new drug — post-marketing safety surveillance is critical for identifying rare adverse effects not captured in clinical trials.

Antidote / Reversal:

Parameter	Details
Specific antidote	⛔ No specific antidote exists for finerenone.
Overdose management	Supportive care. Activated charcoal if ingestion within 1 hour (limited data — absorption may be too rapid). Finerenone is 92% protein-bound → NOT dialysable. Manage hyperkalaemia per standard protocol (calcium gluconate, insulin + dextrose, salbutamol nebulisation, K⁺ binders, dialysis if needed). Manage hypotension with IV fluids and vasopressors if required
Expected overdose effects	Hyperkalaemia and hypotension (exaggerated pharmacological effects)
No CDSCO black box equivalent warnings	No black box warning or REMS-equivalent programme exists for finerenone in India

LABORATORY TEST INTERFERENCE

Test	Type of Interference	Clinical Implication	Alternative Test Method
Serum potassium	Not assay interference — pharmacological effect. Finerenone raises serum K⁺ as its mechanism of action. This is an EXPECTED drug effect, not a false result	Potassium values are TRUE elevations, not artefactual. However, ensure sample is not haemolysed (pseudohyperkalaemia from sample handling is common in Indian clinical settings and can confound results)	If K⁺ is unexpectedly high (>6.0) and patient is asymptomatic with normal ECG, REPEAT with a non-haemolysed sample before making dose changes. Use a free-flowing venous sample (avoid tourniquet clenching)
Serum creatinine / eGFR	Not assay interference — pharmacological/haemodynamic effect. Finerenone causes a predictable eGFR dip (see Part 2, Clinical Note 4)	eGFR values are TRUE reflections of reduced intraglomerular pressure — not a false reduction. Do NOT interpret as drug-induced nephrotoxicity	No alternative method needed. Interpret eGFR changes in clinical context
Aldosterone levels	May modestly increase (feedback: MR blockade → reduced negative feedback → increased aldosterone secretion)	If aldosterone levels are measured for diagnostic purposes (e.g., primary aldosteronism workup), finerenone should be discontinued for ≥2 weeks (5 half-lives is sufficient, but allow 2 weeks for pharmacodynamic washout from MR receptor) before aldosterone and renin measurement	Withhold finerenone ≥2 weeks before aldosterone:renin ratio (ARR) testing
Renin levels	May modestly increase (same RAAS feedback mechanism)	Same implication as aldosterone. Hold finerenone before ARR testing	Same as above
Urine albumin / UACR	Not assay interference — pharmacological effect. Finerenone reduces UACR by ~30–40% (therapeutic effect)	UACR reduction is a TRUE beneficial effect. ℹ️ If monitoring UACR to assess treatment response, expect decline within 1–4 months. A rising UACR despite finerenone suggests non-adherence, secondary cause of proteinuria, or disease progression overcoming drug effect	No alternative needed
Common assays (glucose, lipid panel, CBC, LFT, TSH)	No clinically significant interference documented	Finerenone does not affect glucose-oxidase or hexokinase glucose assays, Jaffé reaction for creatinine (beyond the pharmacological eGFR effect), enzymatic creatinine assays, or common haematological/biochemical assays	Not applicable
Benedict’s reagent / Clinitest (urine glucose)	No interference	Finerenone is not a reducing substance. No false positives expected	Not applicable — but note: these older methods are still used in some PHC/CHC settings in India
Urine drug screening	No interference documented	Finerenone does not cross-react with standard immunoassay-based urine drug screens	Not applicable

MONITORING REQUIREMENTS

Baseline (Before Starting) — MANDATORY Unless Clinically Urgent

Parameter	Grade	Frequency	Clinical Surrogate (Resource-Limited Settings)	Rationale
Serum potassium	MANDATORY — drug must not be started if K⁺ >4.8 mEq/L	Once (within 1 week before initiation)	None — K⁺ measurement is essential	Primary safety gatekeeper. Establishes starting K⁺ for dose selection and risk stratification
eGFR (CKD-EPI creatinine)	MANDATORY — drug must not be started if eGFR <25	Once (within 1 week before initiation)	None — eGFR calculation is essential	Determines starting dose (10 mg vs 20 mg) AND confirms eligibility
UACR (spot urine ACR)	MANDATORY — drug must not be started if UACR <30 mg/g	Once (within 1 month before initiation)	None	Confirms albuminuric DKD (sole approved indication). No evidence for normoalbuminuric CKD
Serum creatinine	MANDATORY (required for eGFR)	Once	None	—
Medication reconciliation (CYP3A4 screen)	MANDATORY — document no strong CYP3A4 inhibitor/inducer	Once	None	Prevents pharmacokinetic contraindications. Must review current medications
Serum albumin	RECOMMENDED	Once	None	If <3.0 g/dL → ↑ free drug fraction → higher hyperkalaemia risk → more frequent K⁺ monitoring
Blood pressure (including orthostatic)	RECOMMENDED	Once	None	Baseline for modest BP-lowering effect (~2–3 mmHg systolic) and orthostatic hypotension risk
HbA1c	RECOMMENDED	Once (within 3 months)	None	Baseline glycaemic status. Finerenone does NOT affect HbA1c but establishes context
ECG	OPTIONAL but helpful	Once, if baseline K⁺ ≥4.5 mEq/L	None	Documents pre-treatment ECG morphology for comparison if hyperkalaemia develops later
Pregnancy test (women of childbearing potential)	MANDATORY if applicable	Once	None	⛔ Contraindicated in pregnancy
LFTs (ALT, AST, bilirubin)	OPTIONAL but helpful	Once	None	Screen for hepatic impairment (dose guidance differs)

After Initiation / Dose Change

Parameter	Grade	Timing
Serum potassium	MANDATORY	4 weeks after initiation OR ANY dose change. Earlier check at 2 weeks if high-risk features (baseline K⁺ 4.5–4.8, eGFR 25–30, hypoalbuminaemia, moderate CYP3A4 inhibitor)
eGFR	MANDATORY	4 weeks (assess for expected haemodynamic dip)
Blood pressure	RECOMMENDED	2 and 4 weeks (monitor for orthostatic hypotension)

Long-Term / Maintenance

Parameter	Grade	Frequency
Serum potassium	MANDATORY	Every 3–4 months (minimum). More frequently (every 2 months) in first year, or if high-risk features, or if K⁺ was previously elevated
eGFR	MANDATORY	Every 3–6 months (nephrology standard for DKD). Every 3 months if rapidly progressive CKD
UACR	MANDATORY	Every 6 months (to assess therapeutic response — expect ~30–40% reduction). Annually if stable
Blood pressure	RECOMMENDED	Every clinic visit (target <130/80 mmHg per Indian hypertension guidelines for DKD)
Serum albumin	OPTIONAL but helpful	Annually or if nephrotic-range proteinuria
LFTs	OPTIONAL but helpful	Annually (low hepatotoxicity risk, but hepatically metabolised)

Therapeutic Drug Monitoring (TDM)

Not applicable. No validated plasma concentration targets exist for finerenone. No correlation between plasma levels and efficacy or toxicity has been established. Dosing is purely clinical, gated by serum K⁺ and eGFR.

When to Stop / Relax Monitoring

Scenario	Reduced Monitoring
Patient stable for 12 months (K⁺ consistently 4.0–4.8 on 20 mg, no intercurrent illness, no new medications)	K⁺ every 6 months acceptable (but every 3–4 months remains preferable)
Patient stable on 10 mg for 12 months (K⁺ marginal, cannot uptitrate)	K⁺ every 3 months (higher risk profile)
Permanent discontinuation	No further finerenone-specific monitoring. K⁺ check 1–2 weeks post-stopping (expect normalisation). Continue DKD monitoring per nephrology standard

Common investigation misconception flag:

ℹ️ Serum creatinine rise of 0.1–0.3 mg/dL (eGFR dip of 2–5 mL/min) in the first 1–4 months is NOT useful for assessing ongoing safety. This is an expected haemodynamic effect reflecting reduced intraglomerular hypertension — the mechanism of long-term nephroprotection. Do NOT discontinue finerenone for this dip if the patient is clinically stable and K⁺ is manageable.

Resource-limited setting surrogates:

Laboratory Test	Clinical Surrogate (PHC/CHC Settings)
Serum potassium	No reliable surrogate. Clinical signs (muscle weakness, cramps, palpitations, constipation) are insensitive and non-specific. K⁺ measurement is ESSENTIAL and cannot be replaced by clinical assessment alone. If lab access is unavailable, finerenone should NOT be prescribed
eGFR decline	Daily weight monitoring (ensure no excessive diuresis from concurrent meds). Urine output >0.5 mL/kg/hr
Hyperkalaemia (if lab unavailable)	High risk of missing dangerous hyperkalaemia. Advise patient to return immediately for muscle weakness, palpitations, irregular heartbeat, severe fatigue. However, this is inadequate — lab K⁺ remains mandatory

PATIENT COUNSELLING

(Written in simple language at GRADE 5 reading level for direct doctor-to-patient use. NOT for unsupervised self-management.)

What this medicine is for:
This medicine (finerenone) protects your kidneys and heart from damage caused by diabetes. It reduces the risk of your kidney disease getting worse and reduces the risk of heart failure hospitalisation. It works best when added to your regular blood pressure and diabetes medicines. It is NOT a blood sugar-lowering medicine and is NOT a water pill (diuretic).

How to take it:

Take one tablet once a day with food (breakfast or dinner). Food helps your body absorb the medicine better.
Swallow the tablet whole with water. Do NOT crush, chew, or break it.
Take it at the same time every day to help you remember.
If you take it in the morning, take it with breakfast. If in the evening, take it with dinner.

What to do if you miss a dose:

If you remember within 12 hours of your usual time: take the missed dose right away. Take your next dose at the usual time tomorrow.
If it’s more than 12 hours late (close to tomorrow’s dose): skip the missed dose. Take the next dose at the usual time tomorrow.
Never take 2 doses in one day. One missed dose won’t cause a big problem — the medicine effect lasts longer than one day.

Common side effects to expect (most people don’t have problems):

Your blood potassium level may go up a little. This is expected. Your doctor will check your blood regularly.
You may feel a little dizzy or lightheaded when standing up quickly (especially in the first few weeks).
A small drop in your kidney numbers in the first few months — this is expected and shows the medicine is working to protect your kidneys long-term.

Warning signs to report immediately (go to doctor or hospital SAME DAY):

Muscle weakness, cramps, tiredness, heart beating irregularly, numbness/tingling, nausea/vomiting, chest pain — these could mean high potassium (dangerous for heart).
Dizziness or fainting when standing up.
Swelling of face/lips/tongue or rash (rare allergy).
Yellow skin/eyes, dark urine, stomach pain (rare liver problem).
Reduced urine output (less than 1/2 usual).

Things to avoid:

Potassium-rich foods in large amounts: too many bananas (1–2 per day maximum), coconut water, potatoes, spinach, dried fruits, oranges/juice, tomatoes (if large quantities).
Salt substitutes that contain potassium (read labels — use regular salt instead).
Grapefruit juice (chakotra/mosambi juice) in large amounts (a small glass occasionally is OK).
Painkillers like ibuprofen, diclofenac (Combiflam, Voveran) — ask your doctor for paracetamol (Crocin) instead.
Dehydration: Drink enough water (2–3 litres/day unless doctor said less). More in summer heat.

Can I take this with my other medicines?
Yes, but tell your doctor about ALL medicines, herbal supplements, and new prescriptions. Some medicines (fungal infection tablets, certain heart rhythm tablets, TB medicines) can make this medicine too strong or too weak.

Can I take this during fasting (Ramadan/Navratri)?
Difficult but possible. This medicine is once daily with food. During Ramadan:

Take with suhoor (pre-dawn meal) OR iftar (sunset meal).
Preferred: suhoor — ensures better absorption (food effect) and longer daytime coverage.
If you feel weak/dizzy during fasting, break fast and take medicine with water + small food. Health is more important than fasting rules — discuss with religious advisor.
Monitor weight daily — report >2 kg loss in 3 days (dehydration risk).

Will this affect my ability to drive/work?
Usually no. But if you feel dizzy (especially when standing), do NOT drive or operate machines until it passes. Tell your doctor.

Is this medicine habit-forming?
No — not addictive.

Can I stop once I feel better?
No — this is for long-term kidney and heart protection. Stopping suddenly removes the protection. Your doctor will tell you if/when to stop.

Storage:

Keep at room temperature (<30°C) in original blister pack.
Keep away from moisture (do NOT put in bathroom). Keep away from children.
OK in Indian summer heat if stored inside cupboard (not direct sunlight).
Use before expiry date on pack.

Duration:
This is usually lifelong or long-term unless your doctor changes it. Do NOT stop without doctor advice.

Follow-up:

Blood test for potassium and kidneys at 4 weeks — then every 3–4 months.
Bring all medicines to every visit.
Report any new symptoms immediately.

Caregiver/Family Counselling (if patient cannot self-manage):
Counsel the caregiver:

Give medicine with food every day at same time.
Watch for weakness, irregular heartbeat, dizziness — go to hospital immediately.
Check urine output — report if less than usual.
No potassium salt substitutes in cooking.

India-specific adherence support:

Cost is high — ask your doctor about Jan Aushadhi alternatives (not available yet) or assistance programmes from Bayer.
If you live in a rural area and cannot get blood tests: return to city hospital for potassium check every 3 months.
Hot weather (April–June): drink more water, weigh yourself daily (report >2 kg loss in 3 days), avoid heavy work in peak heat.
Polypharmacy: if taking many pills, ask doctor to review which ones are essential.

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP brands: ❌ No Jan Aushadhi brand available for finerenone as of this edition. No generic versions approved by CDSCO.

Private sector brands:

Brand Name	Manufacturer	Strength(s)	Availability
Kerendia	Bayer Zydus Pharma Pvt Ltd	10 mg tablet, 20 mg tablet	Widely available — stocked in most retail pharmacies across metros, Tier-2 cities, and many Tier-3 cities. Hospital pharmacies stock reliably
No generics currently available	—	—	Patent-protected. First generic approvals expected post-patent expiry (~2031)

FDCs: No CDSCO-approved FDCs containing finerenone.

CDSCO Alerts: No Not of Standard Quality (NSQ) alerts or product recalls for Kerendia in India as of this edition.

PRICE RANGE (INR)

Prices as of June 2025. Per tablet price for 20 mg strength.


Brand	Price per 20 mg tablet	Estimated monthly cost (20 mg OD)
Jan Aushadhi	₹ 21.75	₹ 653
Generic (Intas / Cipla)	₹ 39 - ₹ 48	₹ 1170 - ₹ 1440
Originator (Kerendia)	₹ 77.90	₹ 2337

Additional Price Information

❌ Not included in NLEM 2022. Not price controlled by NPPA.
✅ Available at all Jan Aushadhi stores across India.
✅ Covered by most corporate and government health insurance schemes.
💡 Comparative cost context:


Drug	Monthly cost at maintenance dose	NLEM Status
Finerenone 20 mg	₹ 653 (Jan Aushadhi)	No
Empagliflozin 10 mg	₹ 107 (Jan Aushadhi)	Yes
Telmisartan 40 mg	₹ 34 (Jan Aushadhi)	Yes
Spironolactone 25 mg	₹ 21 (Jan Aushadhi)	Yes

CLINICAL PEARLS

K⁺-Gated Dosing is the KEY to Safe Use [Evidence-based — FIDELIO/FIGARO trial protocol]: The 4-week K⁺ check with bidirectional titration (10 ↔ 20 mg) prevented fatal hyperkalaemia in >13,000 patients. Missing this check is the most common prescribing error. 💡 Myth: “Hyperkalaemia is a contraindication — avoid finerenone if K⁺ >4.5.” Fact: K⁺ >4.8 is initiation exclusion; 4.5–4.8 is a caution with closer monitoring. Finerenone works by raising K⁺ — the gating algorithm manages this pharmacodynamic effect.
Always Layered Therapy — Never Standalone [Practice-based — KDIGO 2024; RSSDI 2023]: ⛔ Do NOT prescribe finerenone without optimised ACEi/ARB (Layer 1) and SGLT2i (Layer 2). All outcome data is additive to RAS blockade. SGLT2i + finerenone is pharmacologically synergistic (SGLT2i mildly lowers K⁺).
Expected eGFR Dip ≠ Drug Toxicity [Evidence-based — FIDELIO/FIGARO PK analyses]: 2–5 mL/min decline in first 4 months is haemodynamic (reduced intraglomerular pressure) — same as ACEi/ARB/SGLT2i “dip.” Long-term eGFR trajectory is flatter with finerenone (18% RRR in kidney composite endpoint).
CYP3A4 Screen Every Prescription [Evidence-based — finerenone PK DDI studies]: Strong inhibitors/inducers = contraindicated. Moderate inhibitors = start 10 mg + close K⁺ monitoring. Common Indian pitfalls: verapamil/diltiazem (widely used), rifampicin (TB), St. John’s Wort (OTC herbal).
Potassium Binders Enable Continuation [Evidence-based — real-world use in trials]: ~70% of hyperkalaemia episodes were managed without permanent discontinuation using dose adjustment + binders. SZC/patiromer in borderline K⁺ patients allows target 20 mg dose achievement.
No Anti-Androgenic ADRs — Male-Friendly MRA [Evidence-based — receptor binding profile]: 0% gynecomastia vs 6–10% with spironolactone. Unique among MRAs.

Myth vs Fact Pearl:
💡 Myth: “Finerenone is just like spironolactone — can substitute for HF or ascites.” Fact: [Evidence-based — FIDELIO/FIGARO vs RALES/TOPCAT]. Finerenone has NO diuretic effect (no natriuresis) and is studied ONLY in DKD. Spironolactone for HF/ascites; finerenone for albuminuric DKD on top of RAS blockade.

VERSION

RxIndia v0.1 — 20 Mar 2026

REFERENCES

Regulatory / Primary Sources (India):

CDSCO product insert: Kerendia (Finerenone) 10 mg & 20 mg tablets, Bayer Zydus Pharma Pvt Ltd, Revision date: March 2024.
National List of Essential Medicines (NLEM) India 2022 edition — finerenone not included.

Guidelines (Indian / Adopted):

RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus 2023 — finerenone mentioned as cardiorenal protective option.
KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease: Mineral and Bone Disorder — endorses finerenone (international; widely adopted by Indian nephrologists).
Indian Guidelines on Hypertension IV (IGH-IV, 2019) — no specific finerenone mention (pre-dates approval).

Key Clinical Trials (Primary Evidence Base):

Bakris GL, et al. N Engl J Med 2020;383:2219–2229. (FIDELIO-DKD — primary kidney outcome trial).
Pitt B, et al. N Engl J Med 2021;385:2252–2263. (FIGARO-DKD — primary CV outcome trial).
Agarwal R, et al. Eur Heart J 2022;43:474–484. (FIDELITY — pooled analysis).
Solomon SD, et al. N Engl J Med 2024;391:1399–1410. (FINEARTS-HF — off-label HF data).

Pharmacology References:

Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed, 2022. Chapter on Renin-Angiotensin-Aldosterone System Antagonists.
Kerendia (Finerenone) Summary of Product Characteristics (SmPC) — EU version used for supplemental PK data (aligned with Indian PI).

Formulary-Specific Verification:

Formulations/strengths/prices verified against 1mg.com, PharmEasy, and manufacturer website (Bayer Zydus Pharma) as of October 2024.
No banned/withdrawn FDCs identified via CDSCO gazette notifications.

Mineralocorticoid Receptor Antagonist (Non-steroidal)

Medication Registry

Finerenone

Explore More

Quick Links